Organized by the International Atomic Energy Agency (IAEA)

In Cooperation with

American College of Nuclear Medicine (ACNM)

Arab Society of Nuclear Medicine (ARSNM)

Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB)

Asian School of Nuclear Medicine (ASNM)

Asian Regional Cooperative Council for Nuclear Medicine (ARCCNM)

Australian and New Zealand Society of Nuclear Medicine (ANZSNM)

British Nuclear Medicine Society (BNMS)

Canadian Association of Nuclear Medicine (CANM)

European Association of Nuclear Medicine (EANM)

European Federation of Organisations in Medical Physics (EFOMP)

European Society of Radiology (ESR)

International Organization for Medical Physics (IOMP)

International Society of Radiolabeled Blood Elements (ISORBE)

MD Anderson Cancer Center (MDACC)

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Society of Radiopharmaceutical Sciences (SRS)

World Federation of Nuclear Medicine and Biology (WFNMB)

World Molecular Imaging Society (WMIS)

Programme Committee:

T. Becic, IAEA
U. Bhonsle, IAEA
E. Estrada Lobato, IAEA
A. Jalilian, IAEA
R. Kashyap, IAEA
R. Nuñez-Miller, IAEA
J.A. Osso, IAEA
D. Paez, IAEA
T. Pascual, IAEA
G.L. Poli, IAEA
J. Vassileva, IAEA

IAEA Secretariat:

Scientific Secretaries: J.A. Osso, IAEA
D. Paez, IAEA
T. Pascual, IAEA

Administrative Support: L. Fleming
S. Hadzic

Conference Coordination: K. Morrison
M. Khaelss

TC Coordination: A. Shakhashiro

Location of the Conference:

International Atomic Energy Agency
Vienna International Centre (VIC)
M Building
1400 Vienna, Austria
Tel.: (+43 1) 2600 21324
Fax: (+43 1) 2600 7

Working Language: English

Resolutions: No resolutions may be submitted for consideration on any subject; no votes will be taken.

TIMETABLE

Sunday, 04 October 2015

16:00-18:00	Registration	Gate 1

Monday, 05 October 2015

08:00	Registration	Gate 1
08:00	Distribution of conference material	M Building
09:00–09:30	Opening Session	(Boardroom B)
09:30–12:00	Plenary Session I	PET in Cancer Management (Boardroom B)
12:00–13:00	Lunch Break	
13:00–15:00	Plenary Session II	Hybrid Imaging and Other Imaging Techniques in Breast Cancer (Boardroom B)
15:00–16:00	Poster Review-Session I	(See next page for details)
16:00–18:00	Plenary Session III	Theranostics and Personalize Medicine (Boardroom B)

Tuesday, 06 October 2015

09:00–11:00	Plenary Session IV	Hybrid Imaging and Other Imaging Techniques in Paediatrics (Boardroom B)
11:00–11:20	Coffee/Tea Break	
11:20–13:00	Plenary Session V	Ethics, Leadership Education and Regulatory Issues (Boardroom B)
13:00–14:00	Lunch Break	
14:00–16:00	Parallel Session Ia	Hybrid Imaging and Other Imaging Techniques in Gastrointestinal Cancers (Boardroom B)
14:00–16:00	Parallel Session Ib	Radiopharmacy (Conference Room M3)
14:00–16:00	Parallel Session Ic	Medical Physics and Radiation Protection (Conference Room M4)
16:00–17:00	Poster Review – Session II	(See next page for details)
17:00–18:00	Plenary Session VI	Special Plenary Session- Supply of Molybdenum-99 (Boardroom B)

Wednesday, 07 October 2015

09:00–10:40	Plenary Session VII	Hybrid Imaging and Other Imaging Techniques in Lymphoma (Boardroom B)
10:40–11:00	Coffee/Tea Break	
11:00–13:00	Plenary Session VIII	Hybrid Imaging and Other Imaging Techniques in Prostate Cancer (Boardroom B)
13:00–14:00	Lunch Break	
14:00–16:00	Plenary Session IX	Hybrid Imaging and Other Imaging Techniques in CNS conditions (Boardroom B)
16:00–17:00	Poster Review – Session III	(See next page for details)
17:00–18:00	Plenary Session X	Radionuclide Therapies (Boardroom B)

Thursday, 08 October 2015

09:00-10:40	Plenary Session XI	Hybrid Imaging and Other Imaging Techniques in Lung Cancer (Boardroom B)
10:40-11:00	Coffee/Tea Break	
11:00-13:00	Plenary Session XII	PET/CT in Radiation Treatment Planning (Boardroom B)
13:00-14:00	Lunch Break	
14:00-16:00	Plenary Session XIII	Hybrid Imaging and Other Imaging Techniques in Head and Neck Cancer and Melanoma (Boardroom B)
16:00-16:30	Coffee/Tea Break	
16:30-18:00	Plenary Session XIV	Hybrid Imaging and Other Imaging Techniques in Infection and Inflammation (Boardroom B)

Friday, 09 October 2015

09:00–10:30	Plenary Session XV	Guided Intraoperative Scintrigraphy Tumour Targeting (GOSTT) (Boardroom B)
10:30–11:00	Coffee/Tea Break	
11:00–12:20	Plenary Session XVI	Multimodality Imaging Emerging Applications and Indications (Boardroom B)
12:20–13:30	Lunch Break	
13:30–15:00	Plenary Session XVII	Closing Ceremony (Boardroom B)

POSTERS

All posters presented at the IPET 2015 will be eligible for poster awards provided that they are presented in person during the poster sessions.

A selection committee will be appointed by the IAEA to review the posters on display at the conference, attend the poster presentations, and, at the conclusion of the conference, select a predetermined number of posters to receive the award

Poster Award session will take place 14:15-14:45 on Friday, 9th October 2015.

Posters will be displayed as follows in the ground floor corridors of building A, B, and C:

For the listing of posters and the scheduled review sessions please see the back of the programme

Mon, 5 October 2015	Hybrid Imaging and Other Imaging Techniques in Lymphoma, Lung, Head and Neck Cancer and Other Malignancies. PET-CT in Radiation Treatment planning.
Tue, 6 October 2015:	Hybrid Imaging and Other Imaging Techniques in Breast, Pediatric, Prostate, Gastrointestinal and Gynaecological Cancer. Image Guided Therapy and Radionuclide Therapy Radioguided Surgery General Nuclear Medicine, SPECT, and Other
Wed, 7 October 2015	Hybrid Imaging and Other Imaging Techniques in Benign Conditions and CNS/brain Cancer. Member State Experience with PET, Multimodality Imaging and Newer Applications in Diagnostic Imaging, and Related IAEA Projects
Thu, 8 October 2015	Radiopharmaceutical Production Including Good Manufacturing Practices and Quality Imaging Techniques Physics, Instrumentation and Data Analysis Radiation Protection for Personnel and Patients Quality Management in Nuclear Medicine and Diagnostic Imaging Ethics, Leadership and Education for Nuclear Medicine and Diagnostic Imaging Professionals

EXHIBITS

Commercial exhibits will be located in the M building: Ground floor and second floor from Monday to Thursday, 5–8 October 2015.

List of exhibits

Biodex Medical Systems

Elimpex

Iason GmbH

IBA Molecular

Lablogic UK Limited

Scintomics GmbH

Siemens Healthcare GmbH

The fact that the IAEA has made facilities available for companies does not imply that it endorses the equipment and products exhibited.

SUNDAY 04 October 2015

16:00-18:00 Registration and distribution of conference material

MONDAY, 05 OCTOBER 2015

08:00 Ongoing **Registration and distribution of conference material**

09:00–09:30 **OPENING SESSION**

Room: **Boardroom B**

A. Malavasi, IAEA
Deputy Director General
Head of Department of Nuclear Sciences and Applications

D. Yang, IAEA
Deputy Director General
Head of Department of Technical Cooperation

M. Abdel-Wahab, IAEA
Director
Division of Human Health
Department of Nuclear Sciences and Applications

M. Venkatesh, IAEA
Director
Division of Physical and Chemical Sciences
Department of Nuclear Sciences and Applications

MONDAY, 5 OCTOBER 2015

09:30–12:00 **PLENARY SESSION I**
PET/CT in Cancer Management

Room: **Boardroom B**

Chairperson: **Jadvar Hossein, SNMMI**
IAEA Coordinator: **Diana Paez, Joao Osso**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
09:30–10:00	**Henry Bom**	**AOFNMB**	**PET/CT and Molecular Imaging in Developing Countries** 1.Discuss the role of PET/CT and molecular imaging in clinical practice 2.Determine the different factors that affect the practice of PET/CT in developing countries 3.Integrate current practices of PET/CT within the context of best practices
10:00–10:30	**Lale Umutlu**	**ESR**	**The Burden of Cancer and the Role of Imaging Modalities** 1.Get familiar with current global cancer statistics and their effects on patient population 2.Understand the diagnostic capacity and potential benefits of different imaging modalities in screening and early diagnosis of cancer 3.Assess the advantages/disadvantages of PET/CT and PET/MRI for whole-body staging
10:30–11:00	**Homer Macapinlac**	**USA**	**The Importance of PET/CT in Human Health** 1.Provide an overview of the impact of PET/CT imaging on the management of patients and its impact on health care expenditures 2.Review the current use of PET/CT in the multi-disciplinary care of oncology patients, with emphasis on its utility in adaptive therapeutic strategies
11:00–11:30	**Thomas Beyer**	**EFOMP**	**PET/CT or PET/MR? Who Should PET Partner with?** 1.Understand the principles of combined PET/CT and PET/MRI 2.Appreciate the quantitative nature of PET imaging in either modality 3.Review key applications and advantages/disadvantages of each modality 4.Discuss protocol standardization and key elements of high-quality clinical imaging protocols

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
11:30–12:00	**Philip Elsinga**	**Netherlands**	**Radiopharmaceuticals in Molecular Imaging** 1.Understand the principles of the role of molecular imaging in disease management based on the properties of the applied radiopharmaceutical 2.Know the most important production methods of radiopharmaceuticals 3.Know the novel developments in production methods/technology of radiopharmaceuticals that greatly enhance their worldwide availability
12:00–13:00	*Lunch Break*		

MONDAY, 5 OCTOBER 2015

13:00–15:00 **PLENARY SESSION II**
Hybrid Imaging and Other Imaging Techniques in Breast Cancer

Room: **Boardroom B**

Chairperson: **Homer Macapinlac, USA**
IAEA Coordinator: Diana Paez

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
13:00–13:30	**Hosseim Jadvar**	**SNMMI**	**PET/CT Imaging in Breast Cancer** 1.Review the diagnostic utility of PET/CT with FDG in breast cancer 2.Introduce other PET radiotracers that may be useful in imaging evaluation of breast cancer
13:30–14:00	**Rathan Subramaniam**	**ACNM**	**Other Imaging Modalities in Breast Cancer** 1. Discuss the utilization of radiology imaging modalities (non-PET) in the evaluation of breast cancer 2.Determine the limitations of radiology imaging modalities in breast cancer 3.Discuss the role and value of multimodality imaging for breast cancer management
14:00-14:30	**Jacek Koziorowski**	**Sweden**	**New Radiopharmaceutical Developments** 1.Metabolic imaging in breast cancer 2.Receptor imaging in breast cancer 3.Hormone status in the context of imaging in breast cancer
14:30-15:00	**Andrew Ross**	**CANM**	**Read with the Expert: PET/CT, Breast Cancer** 1.Provide understanding of the utilization of 18F-FDG in the evaluation of breast cancer 2.Describe some of the limitations of 18F-FDG in breast cancer 3.Provide information of dedicated PET instrumentation and procedures (PEM) in the evaluation of breast cancer 4.Provide information of other PET tracers being utilized in the evaluation of breast cancer

MONDAY, 5 OCTOBER 2015

POSTER REVIEW SESSION I

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
15:00–16:00	**Thomas Pascual**	**IAEA**	**Meet-the-Authors: Poster Review / Coffee Break and Commercial Exhibits** 1.Discuss the different applications of PET/CT technology and its usefulness in clinical management of patients 2.Propose novel methodologies in medical imaging that would impact patient management**.**
	Reviewers		
	Henry Bom	**AOFNMB**	
	Homer Macapinlac	**USA**	
	Hossein Jadvar	**SNMMI**	
	Rathan Subramaniam	**ACNM**	
	Andrew Ross	**CANM**	
	Murat Fani Bozkurt	**EANM**	
	Helen Nadel	**Canada**	
	Sobhan Vinjamur	**UK**	
	Akram Al-Ibraheemi	**ARSNM**	

MONDAY, 5 OCTOBER 2015

16:00-18:00 **PLENARY SESSION III**
Theranostics and Personalize Medicine

Room: **Boardroom B**

Chairperson: **Andrew Ross, CANM**
IAEA Coordinator: **Rodolfo Nuñez-Miller**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
16:00–16:30	**Marcus Hacker**	**Austria**	**Imaging in Personalized Medicine** 1.Current concepts in oncology, the problem of tumour heterogeneity 2.How to assess tumour heterogeneity by nuclear imaging methods 3."In-vivo tissue characterisation", multitracer / multiparametric imaging 4.Biopsy guiding 5.Response prediction 6.Companion use of specific radiopharmaceuticals with modern targeted therapies in oncology 7.Therapy monitoring
16:30–17:00	**Richard P. Baum**	**Germany**	**Theranostics - a New Horizon for Nuclear Medicine** 1.Discuss the role of theranostics in medical imaging

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
17:00–17:30	**Vijay Kumar**	**ANZSNM**	**Radiopharmaceutical Aspects of the Theranostics in Neuroendocrine Tumours** 1.Different Ge-68/Ga-68 generators in the market 2.Post-processing method to purify Ga-68 from impurities 3.Application of coordination chemistry 4.Availability of different octreotide analogs 5.Development and importance of various linkers to make new Ga-radiopharmaceuticals 6.Conventional linkers and macrocyclic linkers currently used 7.New linkers and their importance 8.Linkers for diagnostic purposes 9.Linkers for therapeutic purposes 10.Application of octreotide analogs for neuroendocrine tumour 11.Application of linker based PSMA for prostate imaging 12.Potential application of bisphosphonate based theranostics agents
17:30–18:00	**Richard P. Baum**	**Germany**	**Read with the Expert: Theranostics** Discuss the role of theranostics in medical imaging using actual cases for image interpretation

TUESDAY, 6 OCTOBER 2015

09:00–11:00 **PLENARY SESSION IV**
Hybrid Imaging and Other Imaging Techniques in Paediatrics

Room: **Boardroom B**

Chairperson: **Murat Fani Bozkurt, EANM**
IAEA Coordinator: **Thomas Pascual**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
09:00–09:30	**Robert Howman-Giles**	**Australia**	**The Role of PET/CT Imaging in the Management of Paediatric Cancers** 1.Discuss the technical aspects involved in PET/CT imaging of paediatric patients 2.Discuss clinical applications for PET/CT in common paediatric cancer 3.Discuss the role for PET/CT in uncommon and rare paediatric cancers 4.Discuss the role of PET/CT in diagnosing complications arising from treatment of paediatric cancers
09:30–10:00	**Helen Nadel**	**Canada**	**Other Imaging Modalities in Pediatric Cancers** Describe the use of correlative imaging to include SPECT, CT, MRI as standalone and as nuclear medicine hybrid techniques in the evaluation and management of children with cancer
10:00–10:30	**Madan Rehani**	**India**	**Dose Optimization in Pediatric Patients** 1.Understand the specific need for dose optimization in children 2.Become familiar with strategies and approaches for dose optimization in nuclear imaging 3.Become familiar with strategies and approaches for dose optimization in CT imaging
10:30–11:00	**Robert Howman-Giles**	**Australia**	**Read with the Expert: PET/CT, Pediatric Cancers** Discuss the role of PET/CT in paediatric cancers using actual cases for image interpretation
11:00–11:20	*Coffee/Tea Break*		

TUESDAY, 6 OCTOBER 2015

11:20–13:00 **PLENARY SESSION V**
Ethics, Leadership, Education and Regulatory Issues

Room: **Boardroom B**

Chairperson: **Helen Nadel, Canada**
IAEA Coordinator: **Uday Bhonsle**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
11:20–11:40	**Sobhan Vinjamuri**	**UK**	**Ethical Issues in Diagnostic Imaging Practice** 1.Discuss ethical principles in medicine 2.Discuss ethical scenarios in daily nuclear medicine practice 3.Explore clinical decision in an ethical context 4.Discuss ethical concepts of the audience
11:40–12:00	**Akram Al-Ibraheem**	**ARSNM**	**Leadership Initiatives in Nuclear Medicine Practice** 1.Importance of having sustainable initiative with specific goals to develop nuclear medicine 2.Methods to advancing nuclear medicine at intra-institutional level 3.Visionary leadership impact 4.Enforcing nuclear medicine in modern oncology practice; case example 5.Leading enterprise to progressing nuclear medicine at local and regional levels 6.Utilizing international resources to advance nuclear medicine in developing countries
12:00–12:20	**Thomas Pascual**	**IAEA**	**Understanding How Learners Learn: Writing Learning Objectives for Educational Activities** 1.Describe Blooms Taxonomy in relation to writing learning objectives 2.Explain the importance of higher order thinking skills in writing learning objectives 3.Explain how to write appropriate learning objectives in order to achieve intended learning outcomes

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
12:20–12:35	**Teressio Varetto**	**Italy**	**Importance of CME Credits in the Lifelong Learning Process** 1.Review the concepts of CME (Continuing Medical Education),CPD (Continuing Professional Development) and Lifelong Learning 2.Provide an overview of UEMS/EACCME accreditation system 3.Discuss the importance of CME credits in the Lifelong Learning process, professional qualification and recertification 4.Introduce the importance of accredited CME evidence-informed practice and CPD lifelong learning programs including interprofessional education, psychosocial and humanitarian aspect of patient care, communication skills and cultural awareness to maintain high quality healthcare services
12:35–13:00	**Sally Schwarz**	**SNMMI**	**US Production of PET Drugs for Clinical and Research Uses** 1.Discuss the regulatory requirements for the production of clinical PET drugs in the US 2.Discuss the regulations that cover the production of PET drugs used in clinical trials 3.Discuss the requirements for the translation of first-in-man PET radiopharmaceuticals
13:00–14:00	*Lunch Break*		

TUESDAY, 6 OCTOBER 2015

14:00–16:00 **PARALLEL SESSION Ia**
Hybrid Imaging Techniques in Gastrointestinal Cancers

Room: **Boardroom B**

Chairperson: **Mohamad Haidar, Lebanon**
IAEA Coordinator: Enrique Estrada

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
14:00–14:40	**Stefano Fanti**	**EANM**	**PET/CT Imaging in Gastrointestinal Cancers** 1.Indication of PET/CT in gastric cancer 2.Indication of PET/CT in colorectal cancer 3.Indication of PET/CT in GIST 4.Use of non FDG tracers in gastrointestinal cancer
14:40–15:20	**Gabriele Masselli**	**ESR**	**Other Imaging Modalities in Gastrointestinal Cancers** 1.Describe the advantages and limitations of CT and MR imaging for evaluating GI tumours 2.Describe the CT and MR protocol for evaluating GI tumours 3.Identify the CT and MR enterography features of GI tumours 4.Explain the advantages of CT and MR enterography for the staging of the GI tumours 5.Discuss use of imaging in evaluating the response to treatment and in detecting tumour progression
15:20–16:00	**Jean Luc Urbain**	**CANM**	**Read with the Expert: PET/CT, Gastrointestinal Cancers** 1.Recognize the normal distribution of 18F-FDG in the abdomen 2.Detect abnormalities in the 18F-FDG uptake in the most common GI cancers 3.Better correlate the 18F-FDG PET findings with the TNM cancer staging 4.Better advocate and advise for the use of PET in gastrointestinal cancers

TUESDAY, 6 OCTOBER 2015

14:00–16:00 **PARALLEL SESSION Ib**
Radiopharmacy

Room: **Conference Room M3**

Chairperson: **Vijay Kumar, ANZSNM**
IAEA Coordinator: Joao Osso

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
14:00–14:30	**Jason S. Lewis**	**WMIS**	**PET Radiopharmaceuticals Beyond FDG** 1.Learn about PET agents for imaging cancer other than FDG 2.Discover about agents that delineate cancer biology other than metabolism 3.Learn about next generation of PET agents for the staging of cancer and monitoring of therapeutic response
14:30–15:00	**Paola Panichelli**	**Italy**	**Cu 64 Radiopharmaceuticals Production and Quality Control** 1.Introduction to theranostics properties of copper 64 2.Method of production of the radioisotope 3.Radioisotope production: passage to industrial production 4.Chemical purification of the radioisotope, observing GMP rules 5.Examples of clinical applications of 64 CuCl
15:00–15:30	**Frank Roesch**	**Germany**	**Ga 68- Radiopharmaceuticals: Current Status and Future** 1.The basics of the 68Ge/68Ga generator 2.The advantages of 68Ga as a positron emitter 3.The 68Ga-labelling strategies utilizing adequate chelate design 4.The most relevant 68Ga-radiopharmaceuticals clinically applied 5.The link between 68Ga-PET and 177Lu-therapy: Theranostics

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
15:30–16:00	**Orhan Suleiman**	**USA**	**Manufacturing Regulations for Imaging Radiopharmaceuticals in the United States** 1.Review current U.S. Food and Drug Administration regulations for the approval of drugs 2.Review specific requirements for approval of radioactive imaging drugs 3.Review current good manufacturing practice (cGMP) guidance and regulations associated with radioactive imaging drugs, primarily positron emission tomography (PET) 4.Discuss the concept of evidence based medicine and how that will impact on radioactive drugs in the future

TUESDAY, 6 OCTOBER 2015

14:00–16:00 **PARALLEL SESSION Ic**
Medical Physics and Radiation Protection

Room: **Conference Room M4**

Chairperson: **Carlo Chiesa, Italy**
IAEA Coordinator: Gian Luca Poli

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
14:00–14:30	**Madan Rehani**	**India**	**Need of Tracking of Patient Doses in Nuclear Medicine and Hybrid Imaging** 1.Learn about developments that create the need for tracking of patient dose 2.Understand different elements in the process of tracking of radiological procedures and dose 3.Learn about status of tracking of doses from x-ray based imaging and nuclear imaging
14:30–15:00	**Jenia Vassileva**	**IAEA**	**IAEA Activities on Radiation Protection in Diagnostic Imaging** 1.Summarize the basic requirements of the International Basic Safety Standards (GSR3) related to diagnostic imaging 2.Learn about tools provided by the IAEA to support implementation and to strengthen radiation protection of patients and staff, e.g. guidelines document, trainings, informational materials, meetings, networking, etc. 3.Learn about outcomes of the IAEA projects related to radiation protection in diagnostic radiology and nuclear medicine
15:00–15:30	**Ivo Rausch**	**Austria**	**QA/QC in PET: Accreditation, Daily QC and More** 1.Why acceptance testing is important and which tests should be performed 2.Why daily QC and what is commonly done 3.What influences quantification in PET apart from technical aspects (patient preparation, work flow)
15:30–16:00	**Satchithanantham Somanesan**	**Singapore**	**Advances of Detector Technology in Nuclear Medicine** 1.Appraising the history of detector technology as used in nuclear medicine 2.Current trends, challenges and demands that have influenced detector technology as well as the advances made in this field

TUESDAY, 6 OCTOBER 2015

POSTER REVIEW SESSION II

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
16:00–17:00	**Thomas Pascual**	**IAEA**	**Meet-the-Authors-Poster Review / Coffee Break and Commercial Exhibits** 1.Discuss the different applications of PET/CT technology and its usefulness in clinical management of patients 2.Propose novel methodologies in medical imaging that would impact patient management
	Reviewers		
	Robert Howman-Giles	**Australia**	
	Teressio Varetto	**Italy**	
	Mohamad Haidar	**Lebanon**	
	Stefano Fanti	**EANM**	
	Jean Luc Urbain	**CANM**	
	Rathan Subramaniam	**ACNM**	
	Marc Seltzer	**USA**	
	Batool Al-Balooshi	**ARSNM**	
	Francesco Giammarile	**France**	

TUESDAY, 6 OCTOBER 2015

17:00–18:00 **PLENARY SESSION VI**
Special Plenary Session- Supply of Molybdenum-99

Room: **Boardroom B**

Chairperson: **VIJAY KUMAR, ANZSNM**
IAEA Coordinator: Joao Osso

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
17:00–17:20	**Kunthi Pathmaraj**	**WFNMB**	**Optimization of Clinical Protocols** 1.Overview of imaging protocols including patient preparation 2.QC/QA processes for equipment and procedures 3.Image analysis methods 4.Training (and accreditation) of staff in clinical and research protocols 5.Examples of SPECT and PET standard clinical and research protocols 6.Implementing appropriate documentation for all these processes
17:20–17:40	**Joao Osso**	**IAEA**	**Status of Mo-99 Supply and New Developments** 1.The importance of Mo-99 and the issues related to Mo-99 supply 2.Alternative methods for the production of Mo-99 and/or Tc-99m 3.The role of IAEA in supporting Mo-99 and/or Tc-99m production by Member States
17:40–18:00	**Panel Discussion**		

WEDNESDAY, 7 OCTOBER 2015

09:00–10:40 **PLENARY SESSION VII**
Hybrid Imaging and Other Imaging Techniques in Lymphoma

Room: **Boardroom B**

Chairperson: **Stefano Fanti, EANM**
IAEA Coordinator: Enrique Estrada

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
09:00–09:25	**Ora Israel**	**Israel**	**PET/CT Imaging in Lymphoma** 1.Present data regarding the FDG avidity in various histologic subtypes of lymphoma 2.Detail patterns of nodal and extranodal disease involvement 3.Discuss the role of FDG-PET/CT in staging and treatment response assessment in various subgroups of lymphoma 4.Discuss recently developed visual and quantitative criteria for evaluation of interim and end-of-treatment studies as well as their impact on risk-adapted strategies
09:25–09:50	**Rathan Subramaniam**	**ACNM**	**Other Imaging Modalities in Lymphoma** Discuss the role and value of multimodality imaging for management of patients with lymphoma
09:50–10:15	**Marc Seltzer**	**USA**	**Read with the Expert: PET/CT, Lymphoma** 1.Identify common patterns of spread by lymphoma and recognize subtypes of lymphoma that have variable or low FDG uptake 2.Discuss and apply current recommendations for performing a standardized interpretation of PET-CT in response assessment of lymphoma 3.Recognize common pitfalls and artefacts in interpreting PET-CT in lymphoma
10:15–10:40	**Julie Sutcliffe**	**SRS**	**Radiolabeled Peptides For Imaging - What We Need to Know** 1.Understand the clinical relevance of peptides as molecular imaging agents 2.Understand the synthesis and validation of radiolabeled peptides for preclinical and clinical applications
10:40–11:00	*Coffee/Tea Break*		

WEDNESDAY, 7 OCTOBER 2015

11:00–13:00 **PLENARY SESSION VIII**
Hybrid Imaging and Other Imaging Techniques in Prostate Cancer

Room: **Boardroom B**

Chairperson: **Mike Sathekge, ISORBE**
IAEA Coordinator: Ravi Kashyap

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
11:00–11:30	**Stefano Fanti**	**EANM**	**PET/CT Imaging in Prostate Cancer** 1.Available tracers for PET imaging of prostate cancer 2.Indication of PET/CT in prostate cancer 3.Usefulness and limitations of PET imaging in prostate cancer
11:30–12:00	**Frederik Giesel**	**ESR**	**Other Imaging Modalities in Prostate Cancer** 1.Understand the challenges in prostate cancer imaging 2.Learn the assessment of T-staging using multi-parametric mapping 3.Get insight in the new tracer substance PSMA 4.Understand the importance of hybrid imaging of MR and PSMA-PET 5.Learn the aspect of theragnostics in PSMA-imaging
12:00–12:30	**Jason S. Lewis**	**WMIS**	**Zirconium 89 and Associated Radiopharmaceuticals** 1.Learn about the expanding use and the inclusion of longer-lived radiometal positron-emitters, such as Zr-89, in PET imaging 2.Review the current state-of-the-art in non-standard PET nuclide application with an emphasis on the use of small molecules, peptide and Zr-89 antibody constructs
12:30–13:00	**Stefano Fanti**	**EANM**	**Read with the Expert: PET/CT, Prostate Cancer** Discuss the role of PET/CT in prostate cancer using actual cases for image interpretation
13:00–14:00	*Lunch Break*		

WEDNESDAY, 7 OCTOBER 2015

14:00–16:00 **PLENARY SESSION IX**
Hybrid Imaging and Other Imaging Techniques in CNS conditions

Room: **Boardroom B**

Chairperson: **Akram Al-Ibraheem, ARSNM**
IAEA Coordinator: Enrique Estrada

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
14:00–14:20	**Emilija Janevik**	**SRS**	**Radiopharmaceuticals in Neurological and Psychiatric Disorders** 1.Understanding the utilization of radiopharmaceuticals for neurological and psychiatric disorders 2.Diagnostic application of SPECT radiopharmaceuticals in neurology and psychiatry 3.Diagnostic application of PET radiopharmaceuticals in neurology and psychiatry 4.Therapeutical application of radiopharmaceuticals in neurology and psychiatry
14:20–14:45	**Andrew Scott**	**WFNMB**	**PET/CT Imaging in CNS conditions** 1.Understand the applications of PET/CT in the evaluation of CNS malignancies, including the evidence for the use of various PET tracers in different clinical scenarios 2.Know the use of PET/CT in the evaluation of patients with epilepsy 3.Understand the evidence for PET/CT in the evaluation of dementia patients
14:45–15:10	**Andrew Scott**	**WFNMB**	**Read with the Expert: PET/CT in CNS Conditions** 1.Understand the patterns of uptake of PET tracers in CNS tumours 2.Interpret PET/CT images of neuroligands in dementia studies 3.Evaluate PET/CT studies in patients with epilepsy
15:10–15:35	**Paul Parizel**	**ESR**	**Other Imaging Modalities in CNS Conditions** Discuss the role of non-PET imaging modalities in benign and malignant CNS conditions

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
15:35–16:00	**Paul Parizel**	**ESR**	**Read with the Expert: Other Imaging Modalities in CNS Conditions** Discuss the role of non-PET Imaging in CNS conditions using actual cases for image interpretation

WEDNESDAY, 7 OCTOBER 2015

POSTER REVIEW SESSION III

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
16:00–17:00	**Thomas Pascual**	**IAEA**	**Meet-the-Authors-Poster Review / Coffee Break and Commercial Exhibits** 1.Discuss the different applications of PET/CT technology and its usefulness in clinical management of patients 2.Propose novel methodologies in medical imaging that would impact patient management
	<u>Reviewers</u>		
	Helen Nadel	**Canada**	
	Murat Fani Bozkurt	**EANM**	
	Stefano Fanti	**EANM**	
	Frederik Giesel	**ESR**	
	Akram Al-Ibraheem	**ARSNM**	
	Andrew Scott	**WFNMB**	
	Mike Sathekge	**ISORBE**	
	Roberto Delgado-Bolton	**EANM**	
	Marc Seltzer	**USA**	

WEDNESDAY, 7 OCTOBER 2015

17:00–18:00 **PLENARY SESSION X**
Radionuclide Therapies

Room: **Boardroom B**

Chairperson: **Mike Sathekge, ISORBE**
IAEA Coordinator: Uday Bhonsle

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
17:00–17:20	**Jadvar Hossein**	**SNMMI**	**Radionuclide Therapy of Prostate Cancer** 1.Discuss the role of radionuclide therapy in the management of prostate cancer 2.Review alpha particle therapy with Ra-223 dichloride in castrate-resistant metastatic prostate cancer 3.Describe the differences in alpha and beta particle therapy
17:20–17:40	**Carlo Chiesa**	**Italy**	**Role of Dosimetry in Radionuclide Therapies** 1.Discuss the role of dosimetry in nuclear medicine therapy 2.Review the easiness of the historical radioiodine therapy of the thyroid cancer 3.Explain the difficulties in the implementation of dosimetric procedures in radionuclide therapies
17:40–18:00	**Juergen Gay**	**Germany**	**Safe Handling of Alpha Particle Emitting Pharmaceutical during Treatment of Bone Metastasis** 1.Describe the characteristics of alpha particle emitting radionuclides 2.Review the advantages of alpha emitters for clinical use 3.Explain how to handled alpha emitters in safely at medical facilities 4.Describe best-practice safety procedures applied for alpha emitters

THURSDAY, 8 OCTOBER 2015

09:00–10:40 **PLENARY SESSION XI**
Hybrid Imaging and Other Imaging Techniques in Lung Cancer

Room: **Boardroom B**

Chairperson: **Jean Luc Urbain, CANM**
IAEA Coordinator: **Ravi Kashyap**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
09:00–09:25	**Dietmar Georg**	**IOMP**	**Radiation Treatment Planning in Lung Cancer** 1.Understand techniques, workflow and procedures in high precision radiation oncology for lung cancer 2.Understand uncertainties in target volume definition 3.Understand technical requirements for imaging patient in treatment position 4.Appraise the added value of PET based target definition for radiation oncology 5.Appraise the potential contribution of PET for response assessment after lung cancer radiotherapy
09:25–09:50	**Homer Macapinlac**	**USA**	**PET/CT Imaging in Lung Cancer** 1.Review the utility of FDG PET/CT in staging, determination of prognosis, and response evaluation, in patients with lung cancer 2.Discuss current diagnostic and therapeutic algorithms incorporating PET/CT imaging in the management of lung cancer patients
09:50–10:15	**Frederik Giesel**	**ESR**	**Other Imaging Modalities in Lung Cancer** 1.Understand the challenges in FDG-PET imaging 2.Differentiate between benign and malignant lesions 3.Understand the importance of N-staging using FDG-PET
10:15–10:40	**Homer Macapinlac**	**USA**	**Read with the Expert: PET/CT, Lung Cancer** Discuss the role of PET/CT imaging in lung cancer using actual cases for image interpretation
10:40–11:00	*Coffee/Tea Break*		

THURSDAY, 8 OCTOBER 2015

11:00–13:00 **PLENARY SESSION XII**
PET/CT in Radiation treatment Planning

Room: **Boardroom B**

Chairperson: **Andrew Ross, CANM**
IAEA Coordinator: **Diana Paez**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
11:00–11:40	**Marco Brambilla**	**EFOMP**	**Biological Target Volume Delineation with 18F-FDG PET/CT for Radiotherapy Planning** 1.Understand the limitations of visual contouring of 18F-FDG volumes for subsequent use in radiotherapy planning 2.Obtain an up to date review of current methods for 18F-FDG volume delineation 3.Obtain an extensive knowledge of the methodological aspects of adaptive thresholding contouring including a discussion on the limitations of such methods
11:40–12:20	**Habib Zaidi**	**Switzerland**	**Image Derived PET Metrics in Monitoring Response to Therapy** 1.Understand the basic limitations of quantitative imaging and PET metrics used in clinical routine, the factors influencing them for subsequent use in assessment of response to treatment 2.Provide a state-of-the-art review of current PET metrics used in clinical and research setting and their limitations 3.Provide an overview of the methodological aspects of more advanced quantitative techniques including radiomics and parametric whole-body imaging requiring the use of dynamic imaging protocols
12:20–13:00	**Eduardo Rosenblatt**	**IAEA**	**Defining Target Volumes and Organs at Risk: A Common Language** 1.Distinguish the various target volume definitions of ICRU Reports (GTV, CTV, and ITV) 2.Determine how these elements are part of a global planning target volume (PTV) construction 3 Describe the elements that influence the definitive shape and volume of the PTV and OAR
13:00–14:00	*Lunch Break*		

THURSDAY, 8 OCTOBER 2015

14:00–16:00 **PLENARY SESSION XIII**
Hybrid Imaging and Other Imaging Techniques in Head and Neck Cancer and Melanoma

Room: **Boardroom B**

Chairperson: **Batool Al-Balooshi, ARSNM**
IAEA Coordinator: **Ravi Kashyap**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
14:00–14:30	**Roberto Delgado-Bolton**	**EANM**	**PET/CT Imaging in Melanoma** 1.Discuss the indications of FDG PET/CT imaging in melanoma 2.Review the advantages and disadvantages of PET/CT in evaluation of patients with melanoma: (a) micro metastases; (b) brain and lung lesions 3.Review the role of FDG PET/CT in evaluation of sentinel lymph nodes 4.Review the new PET tracers for melanoma 5.Review the role of PET/MR in melanoma
14:30–15:00	**Roberto Delgado-Bolton**	**EANM**	**Read with the Expert: PET/CT, Melanoma** Discuss the role of hybrid imaging modalities in the management of melanoma using interactive cases for discussion
15:00–15:30	**Ora Israel**	**Israel**	**PET/CT Imaging in Head and Neck Cancers** 1.Identify and discuss the appropriate use of PET-CT for staging head and neck cancer 2.Identify and discuss the appropriate use of PET-CT for restaging, monitoring therapy, and surveillance of head and neck cancer 3.Describe common pitfalls and challenges in interpreting PET-CT of the head and neck
15:30–16:00	**Marc Seltzer**	**USA**	**Read with the Expert: PET/CT, Head and Neck Cancers** Discuss the role of hybrid imaging modalities in the management of head and neck cancers using interactive cases for discussion

THURSDAY, 8 OCTOBER 2015

POSTER REVIEW SESSION IV

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
16:00–16:30	**Thomas Pascual**	**IAEA**	**Meet-the-Authors-Poster Review / Coffee Break and Commercial Exhibits** 1.Discuss the different applications of PET/CT technology and its usefulness in clinical management of patients 2.Propose novel methodologies in medical imaging that would impact patient management
	Reviewers		
	Madan Rehani	**USA**	
	Sally Schwarz	**SNMMI**	
	Vijay Kumar	**ANZSNM**	
	Jason S. Lewis	**WMIS**	
	Marco Brambilla	**EFOMP**	
	Habib Zaidi	**Switzerland**	
	Dong Soo Lee	**AOFNMB**	
	Jun Hatazawa	**AOFNMB**	

THURSDAY, 8 OCTOBER 2015

16:30–18:00 **PLENARY SESSION XIV**
Hybrid Imaging and Other Imaging Techniques in Infection and Inflammation

Room: **Boardroom B**

Chairperson: **Henry Bom, AOFNMB**
IAEA Coordinator: **Uday Bhonsle**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
16:30–17:00	**Mike Sathekge**	**ISORBE**	**SPECT and PET Imaging in Infection and Inflammation** 1.Review the indications for PET and SPECT in infection and inflammation. 2.Know the criteria for interpretation and of the limitations and pitfalls of PET and SPECT 3.Re-evaluate the role of the radionuclide gold standard; labelled leukocyte/marrow imaging 4.Understand the potential role of new tracers for PET and SPECT
17:00–17:30	**Christopher Contag**	**WMIS**	**Optical Imaging Tools for Early Detection** 1.List some of the needs and challenges for early cancer detection in the clinic 2.Describe the major challenges for optical imaging at high resolution for detection of small numbers of malignant cells 3.List the advantages of optical imaging and some of the tools to achieving improved signal to noise, larger fields of view and more rapid screening

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
17:30–18:00	**Mike Sathekge**	**ISORBE**	**Defining Target Volumes and Organs at Risk:** **A Common Language** 1. Tuberculosis: • Identification active versus non-active TB • Identification of extrapulmonary TB, • Staging of TB, • Assessment of treatment response. 2. HIV: • Know the relationship between positivity of PET/CT scan and immune-virological status • Understand assessing response to highly active antiretroviral therapy and assessing complications. • Develop a strategy on early diagnosis of HAND • Understand the potential role of new tracers such as Ga-68 peptides and the role of F-18 FDG in predicting prognosis in malignancies in HIV positive patients. • Identify the strength and weaknesses PET/CT in investigation of FUO in HIV-positive patients even if they are viraemic. 3. Review use of quantitative imaging to guide treatment strategy and minimize long-term toxicity.

FRIDAY, 9 OCTOBER 2015

09:00–10:30 **PLENARY SESSION XV**
Guided Intraoperative Scintrigraphy Tumour Targeting (GOSTT)

Room: **Boardroom B**

Chairperson: **Roberto Delgado-Bolton, EANM**
IAEA Coordinator: **Rodolfo Nuñez Miller**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
09:00–09:30	**Francesco Giammarile**	**France**	**GOSTT General Concept** 1.Provide an update on the latest advances concerning sentinel lymph node mapping (SLNM) and radioguided sentinel lymph node biopsy (SLNB) for the diagnosis and treatment of patients with cancer 2.Provide a thorough review of the latest experience and literature and to define procedural recommendations on applications of radioguided surgery other than SLNB 3.Describe advances in the implementation of hybrid imaging technologies for the surgical management of patients with cancer in conjunction with intraoperative regional lymph node mapping 4.Discuss the use of small field scintigraphic imaging devices in the operating theatre
09:30–10:00	**Murat Fani Bozkurt**	**EANM**	**GOSTT in Breast Cancer** 1.Obtain an extensive knowledge on the methodological aspect of GOSTT in breast cancer 2.Describe the indications of GOSTT in breast cancer 3.Gain satisfactory information on the clinical use and significance of GOSTT in breast cancer 4.Obtain an up-to-date brief review of literature on GOSTT technique in breast cancer
10:00–10:30	**Francesco Giammarile**	**France**	**GOSTT Other Relevant Applications** 1.Review and discuss the controversies on the use of SLN procedures in different clinical settings 2.Apply decision making process in the implementation of minimally invasive surgical procedures
10:30–11:00	*Coffee/Tea Break*		

FRIDAY, 9 OCTOBER 2015

11:00–12:20 **PLENARY SESSION XVI**
Multimodality Imaging Emerging Applications and Indications

Room: **Boardroom B**

Chairperson: **Andrew Scott, WFNMB**
IAEA Coordinator: **Enrique Estrada**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
11:00–11:20	**Henry Bom**	**AOFNMB**	**Applications of Multimodality Imaging in Cardiovascular Diseases** 1.Explain advantages and disadvantages of SPECT/CT, PET/CT and PET/MRI 2.Explain appropriate & emerging clinical indications of SPECT/CT, PET/CT and PET/MRI for cardiovascular patients 3.List clinical and fundamental research activities using SPECT/CT, PET/CT and PET/MRI for cardiovascular patients
11:20–11:40	**Dong Soo Lee**	**AOFNMB**	**Radionanomedicine: Beyond Multimodal Imaging to Therapy/Theranostics** 1.Understand what is radionanomedicine, and what it is for, especially, in vivo theranostics 2.Envision what kind of unmet clinical needs will be solved by radionanomedicine 3.Take one best example of successful radionanomedicine
11:40–12:00	**Gang Huang**	**ASNM**	**PET/CT: Tumour Response Assessment after Conventional and Targeted Therapy** 1.Know the importance of the tumour response assessment in cancer treatment planning and patient management 2.Understand the differences in mechanisms of tumour-targeted drugs and traditional cytotoxic drugs in cancer treatment 3.Understand the limitations of anatomical imaging techniques for cancer treatment assessment 4.Appreciate the important role of PET/CT imaging in tumour treatment evaluation and investigate its mechanisms in reflecting the tumour response changes, especially with quantitative analysis
12:00–12:20	**Jun Hatazawa**	**AOFNMB**	**Clinical PET in Neurology/Neurosurgery** Discuss PET applications in brain tumours, neurodegenerative disease, epilepsy, and cerebrovascular diseases
12:20–13:30	*Lunch Break*		

FRIDAY, 9 OCTOBER 2015

13:30–15:00 **PLENARY SESSION XVII- Closing Ceremony**

Room: **Boardroom B**
Chairperson: **Thomas Pascual**

Time	*Name*	*Designating Member State/Organization*	*Title of Paper and Objectives*
13:30–14:15	**Ora Israel**	**Israel**	**Highlights & Trends** Synthesize the relevant issues discussed on the role of medical imaging in the management of patients with cancer (and others) and highlight key issues that would affect best practices
14:15–14:45	**Diana Paez, Joao Osso,**	**IAEA**	**Awards**
14:45–15:00	**Diana Paez**	**IAEA**	**Closing Remarks**

POSTERS

MONDAY, 5 OCTOBER 2015

Hybrid Imaging and Other Imaging Techniques in Lymphoma, Lung, Head and Neck Cancers and Other Malignancies

PET-CT in Radiation Treatment Planning

Location: Corridor A, B, C: Ground Floor

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
Hybrid Imaging or Other Imaging Techniques in Head and Neck Cancer and Other Malignancies.			
3	**V. Artiko** B. Radovic S. Odalovic S. Sobic-Saranovic V. Obradovic	Serbia	The Utility of 18F-FDG-PET/CT in Diagnosis and Follow Up in Patients with Adrenal and Neuroendocrine Tumours.
5	**I. Kostadinova** A. Demirev J. Mihailova V. Hadjilska	Bulgaria	Quantitative Measurements of the Therapeutic Effect in Patients with Somatostatin Expressing Tumours Using 99mTc-Tectrotyde
10	**V. Soroa** M. Volpacchio V. Rubio M. Portillo	Argentina	The Sum Is More Than the Parts in PET/CT
32	**J. Mihailovic** N. Prvulovic I. Majdevac D. Manic	Serbia	Diagnostic Accuracy of (18) F-FDG PET/CT in Recurrent Differentiated Thyroid Cancer
33	**J. Mihailovic**	Serbia	(18)F-FDG PET/CT in Thyroid Carcinoma
42	**P. Choudhury** S. Rawat A. Dewan M. Gupta A. Rao	India	Impact of Single End of Treatment 18F-FDG PET-CT in Node Positive (N2) Squamous Cell Carcinoma (SCC) of Head and Neck after Definitive Chemoradiation for Guiding Management and Predicting Outcome
46	**H. Song** J.H. Choi	Republic of Korea	FDG PET/CT Detects Late Onset Sialadenitis After Radioactive Iodine Ablation Therapy
65	**A. Mhiri** F. Ben-Sliméne	Tunisia	Impact of 131I SPECT/ low dose CT on Nodal Staging of Differentiated Thyroid Carcinoma
76	**P. Choudhury** A. Jena M. Gupta	India	PET-CT-MRI Triple Fusion and its Application in Head & Neck Oncology: an Alternative to Integrated PET-MRI in Developing Countries.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
78	**M. Havel** O. Kraft P. Sirucek J. Cvek G. Havlova	Czech Republic	SPECT/CT and PET/CT in Patients with Differentiated Thyroid Cancer Metastases Treated by Stereotactic Ablative Radiotherapy
79	**S. Park** J.H. Song J. Oldan	Republic of Korea	False-Positivity of Regional Nodal Metastasis on F-18 FDG PET/CT Imaging in Primary Cutaneous Squamous Cell Carcinoma
83	**M. Garcheva-Tsacheva** V. Hadzhiyska Z. Mihaylova	Bulgaria	FDG-PET/CT In The Diagnostics of Unknown Primary Tumors
86	**N. Helsen** L. Carp S. Stroobants T. Van den Wynggaert	Belgium	FDG-PET/CT for Treatment Response Assessment in Head and Neck Squamous Cell Carcinoma: a Systematic Review and Meta-Analysis
91	**A. Elliyanti**	Indonesia	Follicular Thyroid Cancer With Skull Metastasis : A Case Report
93	**S. Sidibé**	Mali	Role of Medical Imaging in the Diagnosis and Monitoring of Thyroid Cancer in Bamako, Mali
99	**G. Bruno** **C. Gonzalez** C. Tinetti S. Traverso F. Jaimez N. Bustos	Argentina	Potential use of 18F-NaF-PET/CT for the Detection of Extra-Skeletal Metastases in Osteosarcoma. Comparison with 18FDG-PET/CT
102	**C. Kaewput** P. Pusuwan	Thailand	Diagnostic accuracy of 18F-FDG PET/CT in Differentiated Thyroid Cancer Patients with Elevated Serum thyroglobulin or anti-Tg levels
103	P. Gupta **P. Pankaj**	India	Spectrum of Malignancies Diagnosed on FDG PET CT Presenting as Fuo.
117	**J. Gómez** J. Serna	Mexico	Analysis of the Usefulness of the acquisition of PET / CT with 18F-FDG in Dual Time Point.
121	**A. Jain** P. Pankaj	India	Evaluation of the Role and Incremental Value of 18 F– Fluoro Deoxyglucose PET-CT in Diagnosis of Carcinoma of Unknown Primary
123	**J. Marcinkova** H. Polzerova L. Henzlová P. Koranda	Czech Republic	RhTSH Stimulated 18F-FDG PET/CT in Patients with Thyroid Carcinoma

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
125	**R. Moreira** P. Schiavom-Duarte G. Barberio-Coura-Filho G. Carvalho M. Tatit Sapienza C. A. Buchpiguel	Brazil	Association of Biological and Technical Factors with Extreme Values of SUV on 18f-NaF PET/CT Studies.
140	**B. Doung-Duc** N. Takahito H. Tetsuya	Japan	Ablation Rate and Thyroglobulin Decrease After Low-Dose 131I in Differentiated Thyroid carcinoma Post-Total thyroidectomy
141	**C. A. Stan** C.V. Mazlu	Romania	Diagnostic Performance of PET/CT in Malignant Melanoma
155	**M.F. Ben-Slimene** I. Elbez	Tunisia	Clinical utility of SPECT/CT Versus Planar Bone Scintigraphy in the Daily Practice of the Nuclear Medicine Department of the Salah Azaiez Institute
156	**M.F. Ben Slimene** I. Elbez	Tunisia	Interest of Hybrid SPECT/CT Imaging in the Localization of Ectopic Parathyroid Glands
164	**J. Sejoniene**	Lithuania	Role of Liver MRI and 18F-FDG PET/CT in Atypical Pattern of Metastatic Liver Melanoma
166	**G. Malhotra** R. Kasiliwal A. Lila R. Asopa N.S. Shah M.G.R. Rajan	India	Role of [F-18] FDG PET-CT vis-à-vis [I-131] MIBG in Evaluation of Phaeochromocytomas and Paragangliomas.
167	**B.R. Mittal** R.V. Parghane R.K. Phulsunga A. Bhattacharya J. Shulka	India	Evaluation of Efficacies and Clinical Impact of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in the Diagnosis of Recurrent or Metastatic Medullary Thyroid Carcinoma: A Comparative study in Patient with a Raised Calcitonin Level
175	**D. Jocius** D. Vajauskas	Lithuania	The role FDG PET/CT in Rare Disseminated Pelvic yolk Sac Tumor: Case Report.
176	**A .Sood** B.R. Mittal A. Gorla	India	Incremental value of FDG PET/CT imaging over CECT in the Management of Suspected/ Proven Ddrenocortical Carcinoma: a Correlation with Histopathology
182	**Y. Tuti**	Indonesia	F-18 FDG PET/CT IN Detecting Carcinoma Unknown Primary
186	**A.Q. Buitriago-Gomez** L.K. Anzola Fuentes A. Llamas-Olier	Colombia	Contribution of Hybrid Image in the Diagnosis of Multiple Myeloma: a Case Report.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
189	**M.G. Gama-Moreno**	Mexico	Incidental Thyroid Uptake On 18f-FDG PET/CT Scans In Mexican Population And Correlation With Patologic Results
206	**A.V. Ramachandran Nair** V.H. Somasundaram S.S. Palaniswamy P. Subramanyam	India	Prognostic Value of Volumetric & Metabolic Tumor Parameters in Head & Neck Malignancy.
228	**P. Almeida-Filho** L. Vieira de Carvalho C. Almeida	Brazil	Incidental Hypermetabolic Thyroid Abnormalities on 18F-FDG PET/CT and Correlation with Histological Findings: a Retrospective Analysis
229	**L. Vieira de Carvalho** P. Almeida-Filho C. Almeida	Brazil	Correlation Between Recombinant Human TSH Stimulated 18F-FDG PET/CT Findings and Thyroglobulin Levels on Patients With Differentiated Thyroid Cancer
237	**N.H. Le** **Q.B. Bui**	Vietnam	Value of 18FDG-PET/CT in Detecting Recurrent/Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin and Negative 131I Whole Body Scan
248	**A. Ellmann** A. Doruyter S. Rubow	South Africa	Retrospective Review of Clinical Experience with Ga-68 DOTANOC at the Western Cape Academic PET/CT Centre
257	**L. Louw** S. Said M. Vangu	South Africa	18F-FDG PET/CT Imaging has a Place in Patients with Germ Cell Tumours.
258	**K. Khushica** V. Mboyo Di Tamba Vangu E. Osayande A. Akinwale-Ayeni	South Africa	18F-FDG- PET/CT Imaging in Differentiated Thyroid Carcinoma Patients Who Present with 'Truncated Expression of Sodium Iodide Symporter' Syndrome.
272	**S. A. Khan** A. Sood S. Sharma	India	Effect of Radiotherapy on Salivary Gland in Head & neck Cancer
278	**C. A. De los Reyes Victoria** **M.C. Martinez**	Colombia	F-18 FDG PET/CT in Differentiated Thyroid Cancer, Useful in Clinical Decision Making
295	**Y. Letchumanasamy** **L. Kasilingam**	Malaysia	Does Correlation with Immunohistochemistry Results Increase the Chances of Finding a Primary Site of Malignancy in FDG PET-CT done for Carcinoma of Unknown Primary?
317	R.O. Pinilla-Soto **P. Orellana-Briones**	Chile	PET/CT with 68Ga-DOTA-Peptide Somatostatin Analogue in Non-gastro-entero-pancreatic (GEP) Neuroendocrine Tumors (NET). Initial Experience.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
324	**L. Yamaga** J. Wagner M. Cunha G. Campos-Neto C. Camacho J. Yang M. Funary M. Garcia	Brazil	68Ga-DOTATATE PET-CT in Recurrent Medullary Thyroid Carcinoma: Comparison with 111In-DTPA-octreotide SPECT-CT and Conventional Imaging.
327	**A. Garcia-Resendez** Q. G. Pitalua-Cortes D. Arguelles F. O. Garcia-Perez	Mexico	The Use of 68-ga Somatostatin Analog (dotatoc) PET/CT in the Initial Workup in Neuroendocrine Tumors with Somatostatin receptor Expression: a four-year Review of the Experience in the Instituto Nacional de Cancerolgia (incan.
330	**D. Arguelles** U. Martinez Berry F. O. Garcia Perez	Mexico	Use of SPECT/CT in the Evaluation of Malignant Lesions Spine and its Correlation with Histopathology
352	**J. Das** S. Ray	India	An Analysis of 46 Thyroglobuline Elevated Non iodine secreting (tenis) Syndrome Patients' Data with Respect to Multiple Risk Factors and 18f FDG PET-CT Findings
354	**M. Urhan** E. Akdemir S.A. Ay A. I. Filiz F. Deniz Y. Kurt	Turkey	The Impact of FDG PET/CT Imaging in the Management of Patients with Lodine Negative Thyroglobulin Positive Thyroid Cancer
372	**E. Acar** H. Durak G. Capa-Kaya	Turkey	The Clinical Efficacy and Effectiveness of the Lu-177 DOTATATE Therapy Using Ga-68 DOTANOC PET/CT
376	**D. Valenzuela** A. Haeger P. Orellana Briones J. C. Quintana	Chile	Usefulness of Whole Body 18F-fluoro-2-deoxyglucose Positron Emission Tomography/Computed Tomography in the Detection of Malignancy Neoplasm
382	**E. A. Serrano-Frago**	Costa Rica	Neurosurgical Care in Dealing with High-grade Gliomas that Overexpress the 1p19q Mutation Assessed by Non-hybrid Dusion of SPECT; CT and MRI; Using Gamma Probe Scanning with 99mTc-Sestamibi.
389	**A. Marti Samper**	Colombia	Papillary Thyroid Carcinoma Metastatic to The Pancreas Testicular Cancer Assessment with PET-FDG

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
Hybrid Imaging or Other Imaging Techniques in Lung Cancer			
26	**Z. Zhu** F. Li X. Jin C. Wu K.Zheng	China	Clinical Translation of 68Ga-PRGD2 PET/CT and 99mTc-3PRGD2 SPECT/CT for Integrin Receptor Imaging
28	**D. Sobic-Saranovic** I. Petrusic V. Artiko I. Grozdic-Milojevic S. Odalovic V. Obradovic	Serbia	Comparison of Hybrid Positron Emission Tomography with Computed Tomography and Multidetector Computed Tomography in the Detection of Metastases in Non-Small cell Lung Cancer
43	**M. Hodolic** M. Gabriel Huber Stelzmüller Wunn Hatzl Fellner Lamprecht	Austria	Malignant Incidental Findings on 18F-FDG PET/CT Scans in Patients with Tuberculosis
50	**S. Simon** **I. Elangovan**	India	Role of 18F-FDG PET/CT in Malignant Mesothelioma Follow Up
137	**C. Pieters** V. Lannoy D. Hoton F. Hanin	Belgium	Prognostic value of 18F-FDG PET-CT metabolic parameters in small cell lung cancer: a retrospective study.
163	J. Shaw E. Irusen F. Von Groote-Bidlingmaier **J. Warwik** B. Jeremic R. Du toit C. Koegelenberg	South Africa	Integrated PET-CT for evaluation of mediastinal lymph node staging of non-small cell lung cancer in a Tuberculosis-endemic area: a five year prospective observational study
195	**A. Teyateeti** **A. Teyateeti** P. Pusuwan	Thailand	Impact of 18F-FDG PET/CT Scan on Treatment Decision in Non-small Cell Lung Cancer
196	**A. Teyateeti** **A. Teyateeti** P. Pusuwan	Thailand	A Comparison of Whole Body CT Scan and Whole Body 18F-FDG PET/CT Scan in Evaluation of Non-small Cell Lung Cancer

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
202	**K. Chatti** J. M. Ouvrier D. Benisvy C. Zwarthoed J. Darcourt	Tunisia	18FDG-PET/CT in the Follow Up of Pulmonary Carcinoma Treated by Cyberknife
210	J. Witt T. Graeter **A. Schmidt**	Germany	Some Results of a Seven Years Cooperative Venture between the PET-CT-Unit of the Radiological Center Franken-Hohenlohe and Pulmonary Clinical Center Löwenstein Germany
243	**M. Agolti** **M. S. Cosarinsky**	Argentina	Determining a Value of SUV Maximum Most Probably Related to Non-small Cell Lung Carcinoma in Our Center of Nuclear Medicine
264	**W. Zhai** W. He	China	The Clinical Value of Novel Hybrid 3D Lobar Quantification SPECT Lung Ventilation/Perfusion Scan in Predicting Remaining Lung Function for Lobectomy Lung Cancer Patients
280	**F. O Garcia-Perez** O. Arrieta J.J Del Real Rivas Q. Pitalua I. Soldevilla-Gallardo	Mexico	Prognostic value of αvβ3 integrin ligand [68Ga] DOTA-E- [c (RGDfK)] 2 in patients with non-small cell lung cancer.
335	**A. Calderón**	Colombia	PET/CT In Evaluation Of Malignant Pleural Mesothelioma
378	**K. Maguiña** S. Rojas P. Chávez P. Fernández	Peru	18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET/CT) Scans In Lung Lesions: A 3 Case Report
Hybrid Imaging or Other Imaging Techniques in Lymphoma			
7	**T. Massardo** R. Fernandez J. Jofre P. Sierralta J. Canessa C. Salvo I. Gallegos	Chile	Non-Hodgkin Lymphoma Staging: Relationship of Tumour FDG Uptake and Histological Variants
17	**G. OH** M.S. Lima	Brazil	Lymphoma and Sarcoidosis
18	**J. Jofre** T. Massardo P. Sierralta J. Canessa I. Gallegos R. Fernandez	Chile	FDG-PET in Hodgkin's Disease Evaluation: Characteristics of the Population Referred Between 2003 to 2014

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
19	R. Fernandez T. Massardo **J. Jofre** P. Sierralta J. Canessa I. Gallegos	Chile	Non-Hodgkin Lymphoma Experience with FDG PET: Sample Description, Test Indications and Tumour Histology
20	**J. Jofre** T. Massardo P. Sierralta J. Canessa C. Salvo I. Gallegos	Chile	Hodgkin Lymphoma FDG Staging: Relationship of Tumour Uptake and Histological Subtypes in Classical and Non-Classical Variants
29	**T. Kaewchur**	Thailand	Impact of Intravenous Contrast Medium on Hybrid PET/CT Images in Lymphoma Patients: Experience at PET/CT and Cyclotron Center Chiang Mai University
53	**V. Agarwal** S. Batchu S. Pande S. Sahu N. Gangrade	India	Correlation Between Proliferation Index and Metabolic Activity at the Biopsy Site in Newly Diagnosed NHL
96	**W. Zhai** W. He	China	The Novel Quantitative Software Tool for PET/CT in Staging and Predicting Prognosis of 18F -FDG Avid Lymphoma
122	**L. Henzlová** J. Marcinkova Z. Kapitáňová P. Koranda M. Mysliveček T. Papajík E. Buriankova	Czech Republic	Semiquantitative Analysis of Early 18F-FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma
214	N.Beslic S. Ceric **R. Milardovic** A. Sadija B. Hadžihasanović	Bosnia and Herzegovina	PET/CT Significance in Primary Thyroid Lymphoma (Case report)
234	**N. H Le** **H. S. Mai**	Vietnam	18Flourodeoxyglucose Positron Emission Tomography/computer Tomography (18FDG - PET/CT) in Early Treatment Response Assessment in B-cell non Hodgkin Lymphoma Patients: a Preliminary Result
255	**V. H. Somasundaram** S. Palaniswamy	India	Quantitative Deauville Scale (QPET) in Assessment of Interim 18F-FDG PET in non-Hodgkin's Lymphoma

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
277	**L. Zaabar** N. Willems C. Garcia	Tunisia	Case Report of an Extensive Neurolymphomatosis Highlighted by an 18F-FDG-PET/CT Imaging
336	L. Melillo **G. Bruno** G. de Stefano S. Cugliari M. Miodosky C. Tinettti F. Jaimez S. Traverso M. Namias **C. Gonzalez** M. Zerga P. Parma	Argentina	Diffuse large B-cell lymphomas: Utility of interim 18FDG-PET/CT to Predict Early Treatment Response.
345	**R. Mishra** A. Kumar N. Das J. Cherian D. C. Pandey N. Joshi	India	Is PET/CT More Sensitive Than Bone Marrow Biopsy for Detection of Bone Marrow Involvement in Lymphomas?
PET-CT in Radiation Treatment Planning			
27	**H. Zaidi**	Switzerland	Advances in PET-guided Delineation of Treatment Volumes in Radiation Therapy
54	**R. M. Kanaparthy** H. Tadimeti R. Mohan J. K B. Bob C. Jason B. M K. Krishna	India	Impact of Positron Emission Tomography Images in Stereotactic Body Radiotherapy of Lung Tumours
62	**P. Ballesteros-Zebauda** C.A. Reynoso –Mejía J.M. Lárraga-Gutierrez O.O. Galván de la Cruz S. Rosas González H. Alva -Sánchez M. A. Celis	Mexico	Assessment of Targets Registration Accuracy after Automatic Fusion of CT and PET Images in Radiosurgery Planning

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
100	**J.A. Villalobos** A.C. Jimenez	Costa Rica	Inclusion of PET/CT Scanning and Respiratory Gating in the Radiotherapy Treatment Process of Thoracic Malignancies
151	A. Magli **M. Rensi** E. Moretti **F. Giacomuzzi** F. Titone S. Fongione M.R. Malisan **O. Geatti**	Italy	18F-Choline-PET-CT (PET) in N stage and Radiation Treatment Planning (RTP) of Prostate Cancer Patients (PCap) at High or Unfavorable/intermediate Risk (HUIR)
286	**A. Stefano** G. Russo S. Vitabile F. Marletta C. D'arrigo M. Ippolito	Italy	Biological Target Volume Segmentation for Gamma Knife Treatment.
288	**P. Povinec** A. Masaryková D. Šćepanović M. Pobijakova A. Masaryk	Slovakia	Influence of 18FDG-PET/CT on Radiation Therapy Planning in Patients with Non-small Cell Lung Cancer
351	**C. Cavedon** E. Zivelonghi P.M. Polloniato S. Guariglia M.G. Giri M. Zuffante D. Grigolato M. Cucca R. Mazzarotto M. Ferdeghini	Italy	4D-PET-CT for Radiotherapy Planning: How Many Phase-bins?

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*		*Title of Paper*
366	**H. Mammar** L. Champion O. Madar V. Servois I. Buvat N. Fournier-Bidoz F. Goudjl P. Dass L. Combe F. Lokiec J.L. Albérini R. Belshi A. Labib A. Mazal R. Dendale A. Fourquet	France		Open, phase II trial "Protonchorde01": Improvement Of Local Control In Skull Base and Spine Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by Nitroimidazole ([18F]FAZA) PET/CT

POSTERS

TUESDAY, 6 October 2015

Hybrid Imaging and Other Imaging Techniques in Breast, Pediatric, Prostate, Gastrointestinal and Gynaecological Cancers

Image Guided Therapy and Radionuclide Therapy

Radioguided Surgery

General nuclear medicine, SPECT, and other

Room: Corridor A, B, C: Ground Floor

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
General Nuclear Medicine, SPECT, and Other			
1	**P. Korol**	Ukraine	Comparison of Bone Scintigraphy and X-ray Imaging in Patients after Hip Arthroplasty
21	**M. Maharaj**	South Africa	Tailoring Therapy for Benign Thyroid Disease in Private Practice
25	**R. Heredia** E.Limlingan V. P. Magboo R.A. Conlu	Philippines	The “Raven Sign”: A Case of Apical Left Lung Herniation into the Superior Area of the Right Lung Detected on Tc-99m MAA Lung Perfusion Scintigraphy in a Pediatric Pulmonary Tuberculosis Patient
35	**A. Puente** S. Rosales	Mexico	Pharmacological Treatment and Myocardial Perfusion Abnormalities in Patients with Rheumatoid Arthritis
72	**P. De Silva**	Sri Lanka	Retrospective Study to Determine the Confidence Level in Diagnosing the Secondary Bone Deposits by Tc99 MDP Bone Scans in National Hospital of Sri Lanka
184	**N. Maroz-Vadalazhskaya** E.Slobina	ASNC	Low Diagnostic Value of Invasive Coronary Anatomical Imagine Performed After ECG-stress Test in Patients with Supposed Ischemic Heart Disease
199	**Z. Muyinda**	Uganda	Scintigraphic Pattern Of Osseous Metastases In Breast Cancer At Mulago Hospital, Kampala, Uganda
260	**W. Zhai** W. He	China	A novel SUV-based Quantification of 99mTc-MDP SPECT/CT Uptake and 18F-FDG PET/CT Metabolism in Patients with Lumbar Disc herniation
261	**W. Zhai** W. He	China	Patients with Normal Exercise Stress Myocardial Perfusion Studies Who Achieve Less Than 75 Percent of Maximum Predicted Heart Rate Are at Increased Risk for Cardiac Events
263	**W. Zhai** W. He	China	The clinical Application of Absolute Quantification SUV SPECT 99mTc-MIBI Myocardial Perfusion Imaging to Translate Myocardial Viability ----a Pilot Study

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
265	**W. Zhai** W. He	China	The Clinical Value of SUV Measurements in 99mTC-MDP SPECT/CT Bone Scans in the Evaluation of Therapy Response in Prostate Cancer Patients with Bone Metastases
267	**W. Zhai** W. He	China	The Role of SUV SPECT Perfusion Defect Quantification of the Lung as a Predictor of Severe Cardiovascular Events in a Cohort of Patients with Congestive Heart Failure
274	**A.O. Osman**	Sudan	Glomerular Filtration Rate (GFR) in Patients Taking Nephrotoxic Therapy.
276	**S. Caro** A. Llamas-Olier S. Menendez	Colombia	Surveillance of Papillary Thyroid Cancer Patients Who Received Empiric I-131 Therapy: Can Postherapy Scanning Predict Response to Therapy and Final Outcome?
308	**R. Andropi-Kuru-Embati**	Uganda	Assessing Utility of 99mTc-MDP Bone Scan in Symptomatic Versus Non symptomatic Cases of Cancer at Nuclear Medicine Unit, at Mulago National referral Hospital
361	**A. Quinon**	Philippines	Utilization of Serum thyroglobulin and Anti-thyroglobulin in the Dose Adjustment of Radioactive iodine in the Treatment for Papillary Thyroid Carcinoma
363	**A. Apostol**	Philippines	Clinical Usefulness of Sequential Subtraction Technique in Gastrointestinal Bleeding
377	**P.K Ramdass**	Mauritius	Evaluating the Percentage of Positive Whole Body Bone Scans in Patients with Breast Cancer in Different Periods of Disease
Hybrid Imaging or Other Imaging Techniques in Breast Cancer			
02	**S. Sergieva** E. Alexandrova M. Dimcheva A.Fakirova	Bulgaria	The Use of SPECT-CT for SLN Detection in Breast and Cancer Melanoma
41	**M. Haidar** M. Abu Samra J. Chokr M. Haddad F. Chehade	Lebanon	Role of 18F-FDG PET/CT in Restaging and Management of Suspected Recurrent Breast Neoplasm
88	**G. Estrada** M. Lara-Tamburrino L. Azpeita M. Jiménez	Mexico	War on Breast Cancer Goes Nuclear.High Resolution Breast Positron Emission Tomography: An Emerging Diagnostic Weapon.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
98	**C. Gonzalez** **G. Bruno** M.E. Azar C. Tinetti S. Traverso F. Jaimez N. Bustos C. Noblia A. Osorio	Argentina	Changes in SUV Values on 18FDG-PET/CT Sfter 2 Cycles of Neoadjuvant Chemotherapy May Predict Early Response in Patients with Locally Advanced Ductal Breast Carcinoma
114	**R. Brown** **P.S. Chuah** R. Berhane-Menghis **S. Vinjamuri**	United Kingdom	Significance and Prevalence of Extra-osseous Findings of Low Dose CT Performed with 18F-Fluoride PET/CT Bone scans in Patients with Breast Cancer
152	**D. Grigolato** G. Pollini F. Pellini M. Cucca M. Zuffante M. Barillari E. Zivelonghi R. Pozzi Mucelli C. Cavedon M. Ferdeghini	Italy	Breast Cancer Evaluation: Role of Image Fusion Between FDG PET/CT in Prone position and Magnetic Resonance
179	**R. Vatsa** P. Bhusari J. Shukla B.R. Mittal S. Chakraborty D. Dhawan S. Kumar A. Dash	India	In-house Preparation of Ga-68 NODAGA RGD Dimer as a PET Imaging Tracer for Angiogenesis in Breast Carcinoma
191	**N. Li** Z. Yang	China	The Application of 18F-FDG PET / CT in Follow Up of Breast Cancer Patients with Elevated Tumor Marker
193	**J.H. Lee** **Y.H Ryu** T.J. Jeon J. Jeong	Korea	Variability in FDG Uptake of Primary Tumor According to Acquisition Position Measured on FDG PET/CT of Breast Cancer Patients
201	**H. Budiawan** G.J. Cheon H.J. Seo J.K. Chung J.C. Paeng K.W. Kang D. S Lee	Indonesia	Predisposing Sites of Single Bone Metastasis in Patients with Primary Breast Cancer Detected on F-18 FDG PET/CT

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
204	**A. Damian** M. Rodriguez-Taroco O. Alonso H. Engler	Uruguay	FDG PET/CT for the Detection of Recurrence in Asymptomatic Patients with Increased Serum CA 15-3 levels
205	**A. Damian** C. Espalter N. Silverya L. Delgado O. Alonso H. Engler	Uruguay	18FLT PET/CT for Early Assessment of Chemotherapy Response in Advanced Breast Cancer Patients.
221	**D. Salama** H. Gewefel	Egypt	Accuracy of Combined Breast Ultrasound and Mammography Versus Breast Ultrasound Alone: Not All Mammography Examinations in Young Women
222	**B. Gunalp** S. Ince N. Arslan	Turkey	Importance of FDG-PET/CT Findings in Primary Staging and Clinical Management of Patients with Breast Cancer
259	**F. Mansouri** H. Mahtout	Algeria	Using Hybrid Imaging (SPECT-CT) To Identify A Particular Reason Of Single Hmdp- 99mtc Uptake in the Context Of Breast Cancer.
306	**I. Soldevilla Gallardo** F. O. Garcia Perez J.J. del Real-Rivas E. Estrada-Lovato	Mexico	Value Added of Positron Emission Mammography with Fluorine-18 Fluorodeoxyglucose in the Management of Locally Advanced Breast Cancer
329	**Q.G. Pitalua-Cortes** F.O. García Pérez D. Arguelles	Mexico	Breast Cancer Inmunophenotipic Heterogeneity, Evaluation by Molecular Imaging
333	**A. Garcia-Resendez** M. Patino-Zarco I. Soldevilla-Gallardo F.O. Garcia-Perez	Mexico	Breast Cancer: Role of Molecular Imaging
338	**J. G. Rank** A. G. Garcia-Canizo M. Hjelt	Argentina	18F-FDG PET/CT Demonstrates Objective Response to Alternative Chemotherapy in Breast Cancer
339	**H. Indrawati** H. Budiawan	Indonesia	The Advantage of FDG PET/CT in Staging of Young Population with Breast Cancer
Hybrid Imaging or Other Imaging Techniques In Paediatric Cancers			
107	**A. Abaza** G. El-Shanshoury	Egypt	Evaluation of PET/CT Role in Diagnosis and Management of Pediatric Malignancy

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
144	**R. Delgado** H. Vera	Mexico	PET-CT: An evolve area in Pediatrics.
337	I.V. Batista-de Lacerda **S.C Soares-Brandão** F.R. de Andrade-Lima M. L. de Oliveria	Brazil	Preliminary Dose Assessment in Pediatric Patients Undergoing PET/CT in Recife/PE in Brazil
Hybrid Imaging or Other Imaging Techniques in Prostate Cancer			
14	**F. Hasford** J. H. Amuasi A. K. Kyere M. Vangu	Ghana	Ultrasound and PET-CT Image Fusion for Prostate Brachytherapy Image Guidance
39	**M. Haidar** M. Haddad F. Chehade A. Zaghal J. Chokr	Lebanon	The Impact of 18F-Choline PET/CT in the Staging and Restaging of Prostate Cancer
49	**J. Soto Andonaegui** P. Bezaury Rivas J. Altamirano Ley	Mexico	PET/CT with 11C-Acetate versus 18F-FDG in Patients with Recurrence Biochemistry of Prostatic Carcinoma
77	**J. Garcia** M. Soler M. Moragas M.P. Cozar P. Bassa E. Riera J. Ferrer	Spain	Usefulness of 11c-choline PET/CT in Disease Staging and Therapeutic Management of Prostate Cancer Patients
92	**P. Pankaj** **A. Kumar**	India	Role of 68-Ga Labeled PSMA PET CT Scan in the Evaluation of Prostate Cancer and its Correlation with Histopathology Findings. Preliminary Analysis.
110	**E. Etchebehere** J. Araujo P. Fox N. Swanston H. Macapinlac E. Rohren	USA	The Role of Interim 18f-fluoride PET/CT in Patients Submitted to Radium-223 Therapy
136	**S. Viswanathan** K.V. Setty	India	Scinitmetric Characterization of Skeletal Hot Spots in Carcinoma Prostate

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
256	**L. Maffioli** **L. Dellavedova** M. Carletto	Italy	Is the Biology of Prostate Cancer Related to 18F-Choline Uptake on PET/CT Scans? A Correlation with PSA Values and Gleason Score
347	**S. Ballal** P. Chakraborty P. Thakaral M. Tripathy J. C. Das C. Bal	India	68Ga-PSMA PET/CT in the Evaluation of Prostate Cancer Patients
350	**M. Modiselle** M. Vorster M. Sathekge	South Africa	Association of F-18 flouroethylcholine PET CT with Gleason Score in Prostate Cancer.
362	**S. Balogova** L. Michaud A. Esteso V. Nataf V. Huchet D. Avenin C. Dubot K. Kerrou M. Tassart M. Wartski J.P. Lotz J.N. Talbot	Austria	18f-Fluorocholine PET/CT for the Detection Of Progression of Castration-Resistant Prostate Cancer During Treatment
394	**S.A. Vöö** F. Mottaghy	Netherlands	(68)Ga-labelled PSMA as a New Tracer for Evaluation of Prostate Cancer: Its Diagnostic Value in Patients with Biochemical Recurrence of Prostate Cancer
396	**P. Andrzejewski** P. Baltzer J. Knoth P. Kuess S. Polanec G. Goldner W. Wadsak D. Georg T. Helbich P. Georg	Austria	Prostate Cancer Radiation Therapy Response Assessed with [11C]Acetate PET and MPMRI in the Absence of a Hybrid Scanner
Image Guided Therapy and Radionuclide Therapy			
34	**G. Huang** J. Liu	China	PET/CT: Tumor Response Assessment after Conventional and Targeted Therapy

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
61	**Y. Peña-Quian** T. Crombet-Ramos A. Perera-Pintado J.F. Batista-Cuellar L. A Torrez-Aroche A. Prats-Capote I. Mendoza-Hernandez D. Ills-Gonzalez J. Gonzalez-Gonzalez	Cuba	Immunoscintigraphy with 99mTc-hR3 to Evaluate the Efficacy of Treatment with Nimotuzumab in Patients with Prostate Cancer and Bone Metastases
89	**S. Mohamed** R. Al-Mazroui H. Bererhei O. Elshafie S. Sawhney N.Woodhouse A. Al-Jabri	Oman	Well Differentiated Thyroid Cancer: - The Efficiency of Thyroid Remnant Ablation with I-131 after rhTSH Stimulation and After Thyroxin Withdrawal: A prospective Randomized Control Trial.
97	**P.S. Chuah** **R. Brown** I. Hufton G. Jones **S. Vinjamuri**	UK	Local Experience with the Use of 90Y-SPECT/CT and 90Y-PET/CT in the Assessment of 90-Yttrium Microsphere Biodistribution Following Selective Internal Radiation Therapy for Liver Tumours
148	**S. Rahabi** **S.E. Bouyoucef**	Algeria	Radionuclide Therapy with 153Sm-EDTMP in Painful Bone Metastasis
230	**R. Kumar**	India	Initial Experience with PET-CT Guided Biopsy/FNA Using Automated Robotic Arm.
245	**C.A. de los Reyes-Victoria** Y. Herrera F. Bastidas	Colombia	Use of FDG-PET/CT for Peritoneal Carcinomatosis Before Hyperthermic Intraperitoneal Chemotherapy: Clinic Case.
247	**C. Bal** G. Arora S. Ballal M.P. Yadav	India	177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Inoperable and Metastatic Neuroendocrine Tumours: Experience of first 100 Cases from India
252	**L. Pabon-Castilla** A. Alvarez-Paez E. Manzi	Colombia	Experience with 177lu-dotate in Fundacion Valle de Lili of Cali, Colombia.
284	**E. Slobina** T. Dokukina	Belarus	Integrated Modern Neuroimaging (NI) and Image-guided Stereotactic Thermo/Radio Destruction in the Neurological Clinic of Metastatic Breast Cancer
302	**W. Zhang** Y. Zhang	China	Initial Experience of Utilizing Real-Time Intra-Procedural PET/CT Guided Brachytherapy of Lung Cancer

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
323	**L.M. Pabon** A. Alvarez	Colombia	Intracavitary Therapy with β Radiation-Emitting nuclides in Cystic Craniopharyngioma. Case Report
346	**S. Gambhir** A. Prashanth S. Barai H. Lal A. Nath G. Shankar A. Singh M. Ravina N. Kumar	India	Role of Robotic Assisted PET-CT Guided Biopsy in 18F-FDG/Ga68 DOTANOC Avid Suspicious Lesions
379	**M. D'arienzo** M. Capogni V. Smyth M. Cox L. Johansson A. Fenwick J. Solc C. Bobin H. Rabus L.Joulaeizadeh	Italy	Dose Assessment in Molecular Radiotherapy: Need for Standardization and Harmonization of Nuclear Imaging Procedures
398	**S. Paknikar** S.H. Mehr MD **J. Paknikar** L. Nordquist	USA	Weight Loss in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients on Radium-223 Dichloride
Hybrid Imaging or Other Imaging Techniques in Gastrointestinal Cancers			
40	**M. Haidar** M. Haddad F. Chehade J. Chokr A. Zaghal	Lebanon	Lebanese Experience with 68Ga-DOTA-TATE PET/CT in the Diagnosis and Management of Neuroendocrine Tumours
47	**T.H. Tan** B.N. Lee C.Y. Boey	Malaysia	Impact of 18F-FDG PET/CT in Predicting Treatment Plan and Prognostication for Patients with Esophageal Carcinoma
51	**V. Agarwal** S. Pande S. Sahu R. Kavindran	India	Can We Predict Microvascular Invasion in HCC on FDG PET-CT?
52	**V. Agarwal** S. Pande N. Gangrade S. Sahu	India	Cholangiocarcinoma with Metastases to Breast: Rarer Than a Rare Entity

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
63	**S. Pande** V. Agarwal D. Jangid A. Sen	India	Beyond Milan Criteria in Hepatocellular Carcinoma: Does Fluorine-18-Fluorodeoxyglucose (FDG-PET) Hold the Key
81	**F. Liu** H. Zhu C. Xiong C. Li Z. Yang	China	Radio-labeling Micro-PET Study of Ga-68 Labeled Somatostatin Analogue Pasireotide-DOTA for Tumor Imaging
82	**F. Liu** H. Zhu C. Xiong C. Li Z. Yang	China	Preparation and Preliminary Biological Evaluation of Lu-177 Labeled Somatostatin Analogue DOTA-Pasireotide for Tumor Imaging
94	**M. Qodsi-Rad** R. Sadehgi	Iran	Prognostic Significance of 18-F-FDG PET Imaging in Anal Canal Squamous Cell Carcinoma (SCC): a Systematic Review and Meta-analysis of the Literature
101	**A. Pruthi** **P. Pankaj** R. Verma A. Jain **E.S. Belho** H. Mahajan	India	68Ga-DOTANOC PET/CT Imaging in Localizing the Primary Site in Patients Presenting with Metastatic Neuroendocrine Tumors and its Impact on Clinical Decision Making: Experience From a Tertiary Care Centre in India
109	**I. Slim** M.F. Ben Slimene	Tunisia	The Usefulness of 111In - Pentetreotide SPECT/CT in the Assessment of Neuroendocrine Tumours
118	**J. Das** S. Ray S. Benerjee S. Sinha P. Roy	India	Comparision and Correlation of 18f FDG PET-CT, Operative and Histopathological Findings in Gall Bladder Cancer –an Initial Experience
126	**L. Nguyen**	Vietnam	Value of FDG PET/CT in Staging and Prognosis of Primary Esophageal Cancer
129	**K. Vankadari** **P. Pankaj**	India	Yttrium-90 Radioembolization as an Emerging Iocoregional Therapy for Unresectable Hepatocellular Carcinoma and Hepatic Metastases from Various Solid Tumors: a Single-Center Experience of 30 Patients
131	**I. Bandong** J.R. Bandong	Philippines	Diagnostic accuracy of 18F FDG and 68Ga DOTATATE PET/CT in Detection of Neuroendocrine Tumor: A META-ANALYSIS
133	**Z. Kováčová** J. Kubinyi D. Zogala A. Pudlač	Czech Republic	Focal Increased Activity in the Pancreas on 111In Octreotide scan – could 18 FDOPA PET Scan be Helpful?

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
135	**S.E. Bouyoucef** **M. Habbeche**	Algeria	SPECT/CT 99mTc-EDDA/ HYNIC-TOC in the Management of Neuro Endocrine Tumors
168	**R. Parghane** **B. Mittal** R. Bhattacharya	India	Clinical role of 18F- fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for Detecting Recurrence in Follow up Cases of Gastric Cancer after Surgery
172	**K. Agrawal** R. Parghane R. Gupta B.R. Mittal A. Bhattacharya	India	Comparison of ceCT and FDG PET/CT in Staging of Colorectal Cancer
177	**A. Gorla** B.R. Mittal R. Guptha A. Sood R. Kumar A. Bhattacharya	India	Prognostic Utility of Quantitative Metabolic Parameters Derived from Sequential FDG PET/CT Imaging in Patients with Oesophageal Squamous Cell Carcinoma
187	**X. Yan** A. Kasat	Singapore	Characterization and Clinical Significance of 68Ga-DOTA-Peptides in Uncinate Process of Pancreas
232	**A. Llamas-Olier**	Colombia	Well-differentiated Neuroendocrine Tumors with Aggressive Behavior Frequently Display Predominantly Hyperglycolytic Tumors on FDG PET/CT.
235	**H.S. Mai** **N.H. Le**	Vietnam	Value of 18Flourodeoxyglucose Positron Emission Tomography/Computer Tomography (18F-FDG PET/CT) in Detection of Recurrence in Colorectal Cancer Patients
236	**N.H. Le** **H.S. Mai**	Vietnam	Utility of 18fFourodeoxyglucose positron Emission Tomography/Computer Tomography (FDG PET/CT) in Initial Diagnosis and Staging of Patients with Primary Colorectal Cancer
254	**E. Even-Sapir** **V. Kulikov**	Israel	68Ga-PSMA PET-CT in Patients with Prostate Cancer. Initial Experience at the Tel Aviv Medical center
285	**M. Vangu** K. Khushica N.N. Mkhize L. Louw N. Malan S. Dhoodhat	South Africa	The Role of 68Ga- DOTATATE PET/CT Imaging in Patients with 'Known' vs 'Suspected to Have' Neuroendocrine Tumours
289	**A. Banchero** J. Gaudiano	Uruguay	68-Ga-DOTATATE PET/CT in Insulinoma Detection

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
291	**E. Skoura** E. Panagiotidis O. Almukhailed M. E. Caplin I. Kayani R. Syed S. Michopoulou A. Alshammari J. Bomanji	UK	The Role of 68Ga-DOTATATE PET/CT Imaging in Treatment Plan Change in Patients with Neuroendocrine Tumors
292	A.I. Santos T.N. Silva J.P. Teixeira C. Oliveira J. Castanheira H. Duarte D. Costa J. Portugal **J. Santos**	Portugal	Added Advantages of New Nuclear Medicine Radiopharmaceuticals – a Short Neuroendocrine Tumor Series
294	**E. Skoura** E. Panagiotidis O. Almukhailed M. E. Caplin I. Kayani R. Syed S. Michopoulou A. Alshammari J. Bomanji	UK	Influence of 68Ga-DOTATATE PET/CT imaging in the Decision of Peptide Receptor Radionuclide Therapy (PRRT) Administration
314	**T. Kamoun** I. Karfis G. Gebhart C. Garcia	Tunisia	Optimal Therapeutic Management of Metastatic Pancreatic Neuroendocrine Tumors by Complemantary Molecular Imaging (18F-FDG AND 68GA-DOTATATE PET/CT)
342	**S. Gambhir** M. Ravina S. Barai N. Kumar A. Singh D. Singh A. Prashanth S. Verma M. Dixit	India	Efficacy of 18F-FDG-PET/CT for Detection of Suspected Recurrence in follow up of Patients with Carcinoma Gall Bladder

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
357	**M. Urhan** E. Akdemir I. Succulu O. Bilgi B. Karagoz Y. Kurt	Turkey	FDG PET/CT for Delineating Intraabdominal Invasion from Gastrointestinal or Pelvic Malignancies
374	**A. Orunmuyi** M. Vorster **M. Sathekge**	South Africa	CA Oesophagus: Role of PET/CT on Staging and Management
Hybrid Imaging or Other Imaging Techniques in Gynecological Cancers			
16	**M. Maharaj** A. Pirjol	South Africa	A Case of Unsuspected Sarcoidosis on PET/CT in Ovarian Carcinoma
69	**R. Morales** R. Cano	Peru	Radioguided surgery in Vulvar Cancer
158	**B. Kim** B.H. Byun K.C Lee K.M. Kim I. Lim M.H. Kim B.J. Kim S.Y. Ryu S.M. Lim	Republic of Korea	Comparisons of Intratumoral Distribution of 64Cu-ATSM at Dual Time point PET Scan and 18F-FDG PET Scan; Preliminary Results in Patients with Cervix Cancer
160	**S. Chandran** **S. Simon** **I. Elangovan**	India	Efficacy of 18F-FDG PET-CT in the detection of Recurrent Gynaecological Malignancies
171	**R. Kumar** A. K. Gorla R. K. Phulsunga A. Sood J. Shukla A. Bhattacharya B.R. Mittal	India	Clinical Implication of F-18 FDG PET-CT in Restaging of Patients with Endometrial Carcinoma: Experience at a Tertiary Care Center
231	**O. Diop** R.S. Senghor S. Gassama B. Ndong	Senegal	Place of the Sentinel Node in Uterine Cancers: Preliminary Joint Study Between Nuclear Medicine Departments of theHhospital St. Antoine of Paris and General hospital of Grand Yoff of Dakar

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
241	R. Pruzzo H. Amaral E. Hernandez H. Lavados **B. Morales** D. Acuña	Chile	Histologic Correlation Between 18FDG PET/CT And Lumboaortic Lymphadenectomy In Cervix Carcinoma
242	**J. Arma** A. Mollerach I. Hume C. Collaud C. Cianciarelli L. Paganni V. Jager	Argentina	PET/CT and MRI in the Relapse Of Cervical Cancer Followed up in the Same Centre
368	**K. Ololade** N. Mokgoro M. Modiselle M. Sathekge	South Africa	18F-FDG PET/CT: Metastatic pattern in HIV Positive Patients with Recurrent Cervical Cancer
Radioguided Surgery			
70	**R. Morales** R. Cano M. De la Cruz V. Polar	Peru	Correlation Between Sentinel Node Lymphoscintigraphy and Guided Surgery in Acral Melanoma Patients
332	**S. Medina** F.O. Garcia Perez D. Arguelles Q. G. Pitalua Cortes A. Garcia Resendez	Mexico	Radioguided Parathyroidectomy: A Single Center Experience In Mexico.
364	**J. Mullo**	Peru	Use of Small External Devices for Location of Oncological Injury with 18F-FDG PET/CT

POSTERS

Wednesday, 7 OCTOBER 2015

Hybrid Imaging and Other Imaging Techniques in Benign Conditions and CNS/brain Cancers

Member State Experience with PET, Multimodality Imaging and Newer Applications in Diagnostic Imaging, and Related IAEA Projects

Room: Corridor A, B, C: Ground Floor

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
Hybrid Imaging or other Imaging Techniques in Benign Conditions			
08	**P. Mohan** G. Shroff H. Mahajan	India	Molecular Imaging in Response Evaluation to Human Embryonic Stem Cell Therapy in Neurodegenerative Diseases
12	**T. Massardo** J. Canessa J. Jofré P. Sierralta	Chile	Fluorine-18 Fluoro-2-Deoxy-D-Glucose is Helpful in Castleman's Disease Therapy Assessment
13	**R. Yudistro** R. Fransisca I. Dewi-Muljanto	Indonesia	Correlation Between Glucose Metabolic Uptake Value and Clinical Cognitive Assessment Tools in Patients with Dementia
22	**P. Sierralta** J. Jofre J. Canessa T. Massardo	Chile	Our Experience with FDG and Oral Propranolol to Minimize Brown Adipose Tissue (BAT) Uptake.
23	**N.E. Kerik-Rotenberg** I.E. Diaz-Meneses A. Reynoso-Mejia S. Rosas-Gonzalez	Mexico	18F-FDG PET-CT in Differentiating Dementias
24	**I. Diaz** N. Kerik	Mexico	Initial Clinical Experience with 11C-DTBZ PET for Movement Disorders at the National Institute for Neurology and Neurosurgery of Mexico
44	**I. Elangovan** **S. Simon**	India	Role of 18F- PETCT in Giant Cell Arteritis Presenting as Chronic Thrombocythemia
55	**G. Bural** S. Türe F. Gelal G. Akhan	Turkey	Fusion of Interictal FDG-PET and MRI is Feasible and Helpful in the Detection of Possible Epileptogenic Region

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
57	**G. Bural** A. Alacacioglu	Turkey	FDG Uptake in Non-Paralyzed Vocal Cord: A Potential Cause of Possible Pitfall on PET/CT Imaging
66	**S. Sidibé** A. Koné B. Niaré	Mali	Contribution of Imaging in the Diagnosis of Stress Fractures in Point «G» Hospital, Bamako Mali.
87	**P.S. Chuah** **R. Brown** **S. Vinjamuri**	UK	Our Experience Using F-18 Florbetapir Brain Imaging as Diagnostic aid in Alzheimer's Disease in a University Hospital in United Kingdom
90	**Z.H. Awang** M.F. Khalil	Malaysia	F-18 FDG PET/CT in Fever of Unknown Origin in Putrajaya Hospital, Malaysian Experience
104	P. Gupta **P. Promila**	India	Evaluation of the Role and Incremental Value of 18f – Fluoro Deoxyglucose PET-CT in Diagnosing the Cause of Fever of Unknown Origin
105	P. Gupta **P. Promila**	India	Role of FDG PET CT Imaging in Diagnosis and Therapeutic Response Evaluation in Tuberculosis
111	**R. Brown** **P.S. Chuah** I. Hufton **S. Vinjamuri**	UK	Local Experience of Using Intravenous 99mTc Macroaggregated Albumin in the Diagnosis of Hepatopulmonary Syndrome
113	**R. Brown** **P.S. Chuah** R. Berhane Menghis **S. Vinjamuri**	UK	Local Diagnostic Performance Using Serial Brain Imaging with 99mTc-HMPAO and 123I-FP-CIT (DaTSCAN) in the Evaluation of Patients with Dementia When Differentiating Alzheimer's Disease from Lewy Body Dementia
146	**M.A. Pineda-Tovar** J.A. Ortega-Ramirez	Mexico	An Optimal Clinical Use of 18-FDG PET-CT for the Evaluation Of Myocardial Viability in Diabetic Patients
147	**S. Alenezi** N. Alnafisi S. Asaad S. Salem	Kuwait	The Added Value of FDG PET/CT in the diagnosis of Chronic Osteomyelitis
153	**D. Grigolato** M. Cucca M. Zuffante M. Merighi A. Forni E. Concia M. Ferdeghini	Italy	The Utility of FDG PET/CT in Left Ventricular Assist Device Infection
216	L. Salazar-Vargas **P. Orellana-Briones** D. Vicentini-Harboe J.C. Pattillo C. Godoy F. de Barbieri	Chile	68Ga-DOTATATE PET/CT in the Guidance of Surgical Management in Neonatal Hyperinsulinism: A Case Report

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
217	**M. Štalc** B. Simonič B. Guzič Salobir B. Vrtovec L. Ležaič	Slovenia	Assessment of Myocardial Contractile Reserve Added to Perfusion/Metabolism (SPECT-CT/PET-CT) Viability Study
219	**Z. Ozcan** Y. Ceylan M. Argin S. Bayraktaroglu A. Oral A. Akgun	Turkey	Tuberculous Spondylitis: Detection on PET/CT and Correlation with MRI
271	D. Volterrani G. Puccini D. Frosini F. Guidoccio A. Accorroni E. Filidei A. Giorgetti G. Manca R. Ceravolo **G. Mariani**	Italy	[18F]FDG-PET in the Differential Diagnosis of Parkinsonisms on an Individual Basis.
283	**A. Rahmani** A.K. Lawal M.H. Vangu	South Africa	PET/CT imaging in Takayasu's Arteritis – Should It Be the Standard of Reference?
293	**T. Dokukina** E. Slobina	Belarus	Combined Multimodality Modern Neuroimaging (NI) and Image-Guided Thermo/Radio Destruction in the Treatment of Epilepsy
310	G. Marcenaro **P. Orellana-Briones** J.C. Quintana D. Vicentini	Chile	18F-FDG PET/CT in the Evaluation of Vascular Disease
320	**L.M. Pabon Castilla** A.M. Alvarez M. Renjifo F. Medina J.C. Castro J.S. Toro M. Valenzuela E. Manzi	Colombia	Assessment of Vulnerable Atherosclerotic Plaque Using 18F-FDG PET/CT
321	**K. Maguiña** P. Chavez	Peru	Increased 18F-Fluorodeoxyglucose PET/CT Uptake in Benign Eccrine Poroma Simulating Melanoma

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
322	A.M. Alvarez **L.M. Pabon Castilla** M. Renjifo M. Valenzuela F. Medina J.S. Toro	Colombia	Diagnostic Utility of 18F-FDG PET/CT in Infectious and Inflammatory Disease: Case Reports
334	**J.H. Lee** S.G.Park	South Korea	The Relationship Between Testicular FDG Uptake and Clinical Parameters.
359	L.Michaud **S. Balogova** A. Burgess J. Ohnona V. Huchet K. Kerrou M. Lefrvre M.Tassart F. Montravers S. Perie J.N. Talbot	Austria	A Pilot Comparison of 18f-Fluorocholine PET/CT, Ultrasonography and 123i/99mtc-Sestamibi Dual-Phase Dual-Isotope Scintigraphy in The Preoperative Localisation of Hyperfunctioning Parathyroid Glands In Primary or Secondary Hyperparathyroidism - Influence of Thyroid Anomalies
375	A. Haeger **D. Valenzuela** J.C. Quintana P. Orellana Briones	Chile	68Ga DOTATATE PET/CT Uptake in Vertebral Hemangioma
383	**E. Mora-Ramirez** I. Berrocal-Gamboa	Costa Rica	CZT GAMMA camera multi-pinhole and thyroid imaging. Preliminary experience
386	**A. Marti Samper**	Colombia	18 F-FDG PET/CT Interictal Seizure Focus Localization
387	**M.C. Martinez** **M. Hernandez**	Mexico	Utility of Studies with FDG PET in Patients with Takayasu´s Arteritis
Hybrid Imaging or Other Imaging Techniques in CNS/Brain Cancer			
74	**S. Ray** J. Das A. Chandra R. Schrimali S. Chatterjee	India	Incremental Value of Routinely Including Brain as aPpart of the Whole Body FDG PET-CT and Use of contrast for Staging NSCLC - Its Efficacy and Comparison with MR Imaging of Brain for Detection of Asymptomatic Brain Metastases
162	**L. Cai** S. Gao Y. Li Y. Wang H. Yang	China	18F-FDG,11C- MET, and 11C-CHO PET/CT in the Preoperative Evaluation of Suspected Adult Gliomas

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
282	**N. Mkhize** M. Vangu N. Muambadzi N. Malan	South Africa	18F- FDG PET-CT Imaging of Patients with Extra-cranial Primary Cancer: Routine or Elective Inclusion of Brain in the "Whole Body" Protocol?
287	**E. Slobina** N. Maroz-Vadalazhskaya	Belarus	Diagnostic Possibilities of Multimodality Imaging in Cardiological and Neurological Clinic of Metastatic Colon Cancer
290	**C. Bentancourt** G. Lago A. Quagliata R. Castro A. Damian H. Engler	Uruguay	11C-Methionine and 18 F-FMISO in the Diagnosis, Surgery and Radiotherapy Planning of Patients with Glioblastomas
296	**F.Z. Muftuler** A.Y Kilcar V. Evren E. Medine V. Tekin P. Unak	Turkey	A Novel Brain Imaging Agent for Diagnosis of Alzheimer's Disease; 99mTc-BH
297	**Y. Letchumanasamy** **L. Kasilingam**	Malaysia	Incidental Finding of Cerebral Hypometabolism in Patients Undergoing F18-FDG PET-CT for Various Malignancies.
301	**Y. Letchumanasamy** **L. Kasilingam**	Malaysia	The Role of F18-FDG PET-CT in the Pre-surgical Epilepsy Evaluation - Malaysian Experience.
325	A.M. Alvarez **L.M. Pabon**	Colombia	Role of 18f-FDG PET/CT in the Diagnosis of Rasmussen's Encephalitis.
Member State Experience with PET, Multimodality Imaging and Newer Applications in Diagnostic Imaging, and Related IAEA Projects			
6	**A. Pallewatte**	Siri Lanka	A Study on Experience, Clinical Impact and Limitations of the Only PET/CT Facility in Sri Lanka
9	**I. Kostadinova** K.Minkin P. Dimova D. Zlatareva	Bulgaria	Our First Experience in Application of MRI, PET and Invasive EEG Data in Patients with Drug-Resistant Epilepsy
31	**G. Castro** A. C. Jiménez	Costa Rica	Feasibility of PET/CT in Costa Rica's Social Security System
37	**T. Thientunyakit** N. Wongsururawat C. Hannanthawiwat	Thailand	Relationship between Serum Glucose and F-18 FDG PET/CT Biodistribution Quality in Thai Cancer Patients

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
58	**K. Myint**	Myanmar	First PET-CT and Cyclotron in Myanmar: Challenges and Dreams
108	**D. Piroiu** R.Vladescu C. Popescu	Romania	Comparison between PET-CT, SPECT-CT and Planar Bone Scintigraphy in Following and Managing Cancer with Potential Bone Metastases - Bucharest Emergency Universitary Hospital Experience
115	**N. Ben-Rais** R. Aouad A. Alj H. Guerrouj I. Ghfir M. Farhati	Morocco	Contribution of PET-CT in Infection - Moroccan Experience: Application in Tuberculosis Mimicking a Metastatic Cancer
116	**G. Estrada** J.L. Criales	Mexico	Nucler Medicine Becomes nuclear Against Metastatic Bone Metastases from Prostate Disease. Initial Experience in Mexico, with the Use of Radium-223
130	**M.R. Mitetelu** V.C. Mazilu	Romania	Status of PET CT in Romania
134	**N. Hossain** K.A. Quadir F. Begum T.A. Biman M.A. Azim N. Islam	Bangladesh	Present Status of PET-CT and Cyclotron Facilities in Bangladesh - A Developing Country Profile and Experience
154	**F. Faccio** L. Rios A. Vazquez M. Fleurquin	Argentina	Prevalence of PET/CT Indications According to Diagnosis in a Medical Center in the Province of Santa Fe, Argentina. Treatment Decisions Based on Results
159	T.K. Mai **T.T. Ngo** H.B. Tran D.H. Tran C.D. Le	Viet Nam	PET/CT in the Diagnosis and Treatment of Nasopharyngeal Cancer: Bach Mai Hospital Experiences
169	**S. Hikmawati** K. Kardinah	Indonesia	Indication Appropriateness of 18F-FDG PET/CT Examination in the Dharmais National Cancer Hospital
174	**M.A. Abdul-Khader** I.L. Shuib A. Khoo	Malaysia	Challenges in Setting Up a Nuclear Medicine & PET Training Programme: Triumphs and Tribulations, the Malaysian Experience

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
185	**N.E. Delgado-Lopez** J. Rada F. López C. Sánchez L. de la Rosa J. Otalora A. Llamas A. de los Reyes	Colombia	Radiopharmaceutical production of 68GaDOTATOC at the National Cancer Institute.
203	**C. Laterza** **E**. Yanagida J. Codas Thompson	Paraguay	Initial Experience with 18fdg - Positrons Emission Tomography in Paraguay
208	**S. Nazarenko** A. Samarin L. Karusoo R. Brand M. Paris M. Talk	Estonia	Is the Application of PET Studies Resilient to Recession?
209	**G. Salhi-Cherkaoui** A. Guensi S. Taleb	Morocco	The Daily Use of PET-CT Scan in NHL Patients in Morocco
211	**K. Taalab**	Egypt	An Egyptian FDG PET/PET CT Experience; 11 Years Work
213	**N. Malan** N.N. Mkhize D. Mpanya K. Mokoala M. Vangu	South Africa	Audit of 18FDG PET/CT in the Assessment of Cancer of Unknown Primary in South Africa
223	**M. Zein**	Syria	Optimization of Radio-Iodine 131 Dose in Treatment of Children with Diffuse Lung Metastasis from Thyroid Carcinoma- Local Experience at Al-Assad University Hospital, Damascus.
224	**R.S. Senghor** O. Diop	Senegal	Improving the Management of Cancer Diseases in Senegal
225	**S. Seck Gassama** R. Senghor	Senegal	Preliminary Feasibility Study for the Implementation of a PET-CT Equipment in Senegal
244	**F. Mohammed**	Yemen	Contribution of Nuclear Medicine Services to the Medical Care in Yemen, the Challenges and Impact on Patient Care Management
246	**S. Biswas** Z. Hossain	Bangladesh	Role of 18f-FDG PET-CT Scan for Evaluating Newly Diagnosed Lung Cancer- Experience in Bangladesh
266	**D. Mpanya** A.B. Rahmani E. Hammond M. Vangu	South Africa	Is Cardiac PET imaging for Viability Assessment an Unnecessary Luxury in Developing Countries?

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
270	**C. Mesquita** F. Silva	Brazil	PET CT in Latin America - Brazilian Experience
279	**C. Wieffels** C. Mesquita	Brazil	PET Research in Brazil: How Are We so Far?
305	**A. Anees**	Pakistan	Breast Cancer in Pakistan
309	**A. Eyumu** H. Kadima P. Bayauli S. Ditu	Democratic Republic of Congo	Nuclear Medicine at Democratic Republic of Congo: Still Alive Against All Odds
313	**S. Tarbagdo** H. Sanon F. Ouattara S. Ouedraogo V. Gansore S. Amadou T. Tapsoba B. Ouattara	Burkina Faso	Nuclear Medicine in Burkina Faso Three Years Later: Difficulties and Prospects
315	**L. Karusoo** K. Tomberg A. Samarin S. Nazarenko	Estonia	FDG-PET/CT: Changing Routine Practice in Evaluation of Bone Marrow Involvement in Hodgkin Lymphoma in North Estonia Medical Centre
316	S. Rubow A. Africander **A. Ellman**	South Africa	Preparation of 68Ga-68 Radiopharmaceuticals in a South African Hospital Radiopharmacy
318	**Z. Jawa** I.R. Ahmed	Nigeria	Challenges of Setting up a PET-CT Center in Nigeria
319	**S. Keriba** M. I. Diarra R. Diakite S. Sidibé	Mali	Nuclear Medicine at Mali: Living on a Bad Moment, Having Faith and Highly Committed with the Future
340	**S.C. Saiffudin**	Malaysia	Challenges in Implementing Quality Assurance Programme (Qap) In PET Centres in Malaysia – A Regulatory Perspective.
343	**A. Naojee** H.S.G. Dustagheer	Mauritius	The Growth of Nuclear Medicine in Mauritius
348	R. Yan **S. Li**	China	High Myocardial FDG Uptake in Irradiated Field Observed 3 Months After Radiation Are Related to Myocardial Damage in Beagles by PET/CT with High-fat Diet Protocol
349	**D.N. Prawiro**	Indonesia	The First Year Experience of PET/CT Utilization in the Newly Built Private Hospital

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
353	**H. Sonea** L. Savurimuthu V. Sungkur C. Ahgun H.S. Dustagheer **A. Naojee**	Mauritius	Building Integrity of Nuclear Medicine into the Cardiology Field: the Mauritian Experience
356	**A. Quinon**	Philippines	Establishing Nuclear Medicine Facility Guided by IAEA Publication of Nuclear Medicine Resources Manual- Cagayan de Oro Experience
360	A.M. Alvarez **L.M. Pabon** M. Renjifo J.C. Castro J.S. Toro M. Valenzuela F. Medina E. Manzi	Colombia	Initial Experience Of 18f-FDG PET/CT In The Foundation Clinic Valle Del Lili
365	**N.R. Rakotondralambo** **R.A. Rasata**	Madagascar	Nuclear Medicine in the Public Health Service in Madagascar, Capabilities and Perspectives
369	**L. Adjouati** D. Chenene A. E. Talbi L. Rania A. Zanoune S. E. Bouyoucef	Algeria	Nuclear Medicine at Algeria: Our Country's Experience from the Technologist Point of View
381	**H. Sonea** L. Savurimuthu V. Sungkur C. Ahgun P. Ramdass H.S. Dustagheer A. Naojee	Mauritius	Safety and Effectiveness in Performing Pharmacological Stress Test Using Dipyridamole
384	**M. Kalnina** V. Skrivelis	Latvia	Challenges in Establishing First PET/CT Centre and Cyclotron Facility in Latvia
391	**M. Pedrozo** P. Galván G. Giménez N. Apuril B. Grossling	Paraguay	Nuclear Medicine at the Health Sciences Research Institute, National University of Asuncion): Current State and Projections
395	**B. Ndong** O. Diop	Senegal	Would the TEP-CT with Choline Be Useful for the Patients Reached of Cancer of the Prostate in Senegal

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*		*Title of Paper*
401	**E. Janevik** M. Zdraveska-Kocovska M. Velickovska M. Angeleska K. Kolevska M. Atanasova M. Jancovsca F. Jolevski Z. Filipovski S. Nikolovski N. Ristevska T. Sazdov Z. Spirkovski E. Belopeta	Republic of Macedonia		Unique Pet Facility in Skopje - New Perspective for the Health Care of the Patients in the Balkan Region

POSTERS

Thursday, 8 OCTOBER 2015

Radiopharmaceutical Production Including Good Manufacturing Practices and Quality

Imaging Techniques Physics, Instrumentation and Data Analysis

Radiation Protection for Personnel and Patients

Quality Management in Nuclear Medicine and Diagnostic Imaging

Ethics, leadership and Education for Nuclear Medicine and Diagnostic Imaging Professionals

Room: Corridor A, B, C: Ground Floor

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
Imaging Techniques Physics, Instrumentation and Data Analysis			
4	**G. Sarti** C. Fabbri S. Sanniti F. del Dottore F. Busca	Italy	Pre-Therapeutic Dosimetric Studies and Post-Therapeutic Dosimetric Verification of Nuclear Medicine Therapeutics with SPECT-CT and PET-CT Imaging Systems
15	**F. Hasford** B. Van Wyk T. Mabhengu M. Vangu A.K. Kyere J.H. Amuasi	Ghana	Quantitative Assessment of PET/CT Image Uniformity
48	**M.A. Said** R. Zainon	Malaysia	Evaluation of Factors Affecting Standard Uptake Value (SUV) for Liver Positron Emission Tomography-Computed Tomography (PET-CT) Imaging
59	**H. Mohie el Dein**	Egypt	Effect of Matrix Size and Motion Type on Contrast Parameter in SPECT Studies in Nuclear Medicine
67	**M. de Marco** S. Maggi **L. Falasconi**	Italy	PET/CT Imaging Protocol Optimization for Evaluation of Patients with Implanted Cardioverter Defibrillator
68	**N. Raina** A. Sen A. Pathak D.R. Jangid	India	PET Cardiac Imaging- reconstruction Parameters vs. Diagnostic Information

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
84	**G. Rossi** S. Fattori E. Brianzoni E. Biggi	Italy	124I PET-CT Dosimetry for Nuclear Medicine Therapy
120	**H. Poláček** R. Kaštil I. Režňak	Slovakia	MICADO - A New Collimator Concept and Device for Clinical Nuclear Medicine Imaging.
142	**A.H Ng** S.L. Bugby L.K. Jambi M.S. Alqahtani D. Clay P.E. Blackshaw P.S. Morgan J.E. Lees A.C. Perkins	Malaysia	Hybrid Optical-gamma Camera for Intraoperative Imaging: A Flexible Phantom to Assess System Performances for Sentinel Node Detection
149	**H. Aldousari**	Kuwait	The Hydration Behaviour of Hydrophilic Material in Biological Samples Using Ratio of 3-to-2 Photon Annihilation
157	**J.J. González-González** C.F. Calderón-Marin C. Valera-Corona A. Machado-Tejeda H.J Gonzalez-Correa	Cuba	Philips Gemini TF64 PET/CT Acceptance Testing
192	**J. Cal-Gonzalez** I. Rausch T. Beyer	Austria	PET Quantification as a Function of the Total Acquisition Time in PET/CT
207	I. Rausch **J. Cal-Gonzalez** T. Beyer G. Minear	Austria	Evaluation of the role and incremental value of 18f – Fluoro deoxyglucose PET-CT in diagnosing the cause of fever of unknown origin
238	P.A. de Lucena-Santos **S.C. Soares-Brandão** F.R. de Andrade-Lima J.A. de Lucena-Santos	Brazil	A Preliminary Study on Patient Internal Dosimetry with Neuroendocrine Tumors Undergoing Scintigraphic Examinations Using Computational Phantoms and Radioisotope Sources

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
249	**A. Skopljak-Beganović** A. Beganović M. Gazdić-Šantić N. Salkica A. Drljević	Bosnia and Herzegovina	Effects of Reconstruction Parameters on SUV with NEMA 2007 IQ Phantom
250	**S. Witoszynskyj** P. Andrzejewski B. Knäusl M. Hacker D. Georg	Austria	PET-MR in radiation oncology – How to Correct for Attenuation Caused by Flat Table Top?
262	**W. Zhai** W. He	China	Standardized Uptake Values of 99mTc-MDP SPECT Bone Scans - a Novel Method for Absolute SPECT/CT Quantification
273	**A. Vergara Gil** L.A. Torres Arroches M.A. Coca Perez M. Pacilio F. Botta M. Cremonesi	Cuba	MCID: A Software Tool to Provide Monte Carlo Driven Dosimetric Calculations Using Multimodality NM Images
307	**E. de Ponti** S. Morzenti A. Zorz L. Guerra C. Landoni C. Spadavecchia A. Crespi	Italy	Physical Characterization of the New PET/CT Scanner Discovery IQ (D-IQ)
311	**I. Berrocal-Gamboa** E. Mora-Ramirez M. Torres-Gonzalez C. Fonseca-Zamora	Costa Rica	Imaging Co-Registration: Clinical Applications and Daily Practice
326	**A.C. Fischer** A.M. Marques-da Silva	Brazil	Implementation of a Strategy Towards Harmonization of PET/CT Quantification in Different Devices
344	**N. Das** A. Kumar R. Mishra J. Cherian D. Pandey N. Joshi	India	Comparison of Suv Lean Body Mass Using Tof And Non-Tof Reconstruction Technique.
380	**D. Arguelles** F.O. Garcia Perez Q.G. Pitalúa Cortés U. Martínez-Berry	Mexico	Initial Experience at the Instituto Nacional de Cancerologia (Mexico) of Coregistration of PET / MR Images in Oncological Diseases.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
385	**M. D'arienzo** M.L. Cozzella E. Spezi N. Patterson P. Chiaramida L. Filippi P. Carconi O. Bagni	Italy	90Y-PET Imaging After Liver Radioembolization for the Assessment of the Absorbed Dose to Lesions
390	**H.A. Amaya-Espinosa** W. Stiller L. S. Veloza-Salcedo	Colombia	Image processing for Biological Tumor Volume Definition Based on FDG- PET/CT Imaging: Dynamic and Pharmacokinetic Aspects.
Radiopharmaceutical Production Including Good Manufacturing Practices and Quality Assurance			
36	**L. Xingdang** L. Miao	China	Distributions in the Eyes and Brain of Guinea Pig by Micro-Positron Emission Tomography with Dopamine Transporter Imaging Agent 18F-FECNT
60	**F. Zoppolo** P. Buccino W. Porcal P. Oliver E. Savio H. Engler	Uruguay	11C-SAM: a New Potential Agent for Prostate Cancer Diagnosis
64	**M.A. Azim** K. Shiba T. Kozaka Y. Kitamura	Bangladesh	Synthesis and In Vitro Evaluation of Radiobrominated Benzovesamicol Analogue: Ortho-Bromo-Benzovesamicol as a Potential Sigma-1 Receptor PET Ligand
80	**F. Liu** H. Zhu Z. Yang	China	Preparation and Preliminary Biological Evaluation of Lu-177 Labeled DOTA-TATE
85	**M. Silindir** **A.Y. Ozer** S. Erdogan D. Guilloteau S. Chalon	Turkey	Comparative Evaluation of Pramipexole Encapsulated Theranostic Liposomes and Niosomes for Parkinson's Disease
106	**A. Duran** F. Müller J. Santiñan C. Peñaloza A. Coronel	Argentina	Labelling and Quality Controls of 68Ga-PSMA for Prostate Tumors.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
150	**M.Krošelj** A. Sočan T. Dreger R. Knopp P. Knolenc Peitl	Slovenia	Can sSelf-Shielded Radiosynthesis Box Be Routinely Used for a Fully Automated Small Scale Preparation of Radiopharmaceuticals?
161	**C. Gameiro-Paris** V. Kramer A. Abrunhosa G. Casale **I. Oxley**	Belgium	GMP Manufacturing of Multiple Radiopharmaceuticals in the Same System: IBA Synthera Synthesizer
170	**P. Bhusari** R. Vatsa J. Shukla B. Mittal G. Singh D. Dhawan	India	Development and Radiolabeling of DOTA-Trastuzumab Conjugate as a Probable Probe for Theranostic Application of Her2/neu Expressing Breast Cancers
178	**V. Trindade** N. Bentancor H. Balter H. Engler	Uruguay	Radiochemical Characterization of a 68Ga-labelled PSMA Inhibitor for Prostate Cancer Imaging
180	J. Giglio I. Sanz H. Balter E. Savio **A. Rey** H. Engler	Uruguay	Quality Management System in the Production of Radiopharmaceuticals at the Uruguayan Centre of Molecular Imaging
190	**D. Boddeti** V. Kumar	Australia	Role of Gallium 68 -Labeled Antimicrobial Peptide Ubiquicidin (29-41) in Staphylococcus Aureus Infection Imaging in Animal Model.
198	**S. Nandy** M.G.R. Rajan	India	Synthesis and Evaluation of 1-(2-[18F] Fluoroethyl)-2-Nitroimidazole for Hypoxia Imaging
200	**Y.R. Nitin** S. Nandy **M.G.R. Rajan**	India	Design and Development of a Low Cost Fully Automated Synthesis Module for the Production of Pharmacopeia Grade [18F]NaF

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
220	**L.M. Aonso Martinez** **M.L. Perez-Malo Cruz** A. Xiques-Castillo R. Leyva-Montana M. Zamora-Barrabi A.M. Rodriguez-Sanchez M. Gongora-Bravo Y. Manresa-Sanchez	Cuba	Radiolabeling of Nimotuzumab Fab' fragment with 68Ga and 90Y: a potential Theranostic Agent for EGFR Overexpressing Tumors
226	**K. Smilkov**	Republic of Macedonia	Substance P – A Possible PET Diagnostic Agent
227	**D. Gjorgieva-Ackova**	Republic of Macedonia	Development of Rituximab Radioimmunoconjugates as PET-Radiopharmaceuticals
239	**N. Garg** J. Shulka B. Mittal B. Singh	India	Quality Control of PET/CT Radiopharmaceuticals
240	**P. Unak** O. Kozgus Guldu E.I. Medine F.Z.B. Muftuler A. Y. Kilcar C. A. Ichedef	Turkey	Synthesis of Radioiodine Labeled Functional Magnetic Nanoparticles: L-PHA Lectin Conjugated MNPs and in Vitro Bioaffinities on Cancer Cells
251	**I. Boros** R. Smith F. Aigbirhio	UK	Validation Approach for a New PET Radiopharmaceuticals GMP Facility
253	**K.O. Ogunjobi** **A. Adepoju** O. Popoola A. Orunmuyi	Nigeria	Evaluation of the Labeling Efficiency of Technetium-99m Labelled Red Blood Cells of Breast Cancer Patients Receiving Cardiotoxic Drugs
275	**J. Song** R. Yan Z. Wu J. Li S. Li	China	Detection of Myocardial Perfusion Abnormalities by 13N-NH3 PET/CT and Corresponding Pathological Changes of Beagle Dogs which Heart Was Irradiated Locally
281	**I.U. Khan** A. Shahid F. Ahmad F. Iram M.S. Iqbal	Pakistan	Developing 68Ga-labeled Neuropeptide Y (NPY) Nanoconstructs as Potential PET Imaging Radiopharmaceuticals

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
331	**J.C. Manrique-Arias** M.A. Avila Rodriguez P.G. Reyes-Romero A. Zarate-Morales A. Flores-Moreno V. Lara-Camacho	Mexico	Biodistribution of 64CuCl2 in the Rat: A potencial Tracer for Theranostic Applications
358	**S. Shanehsazzadeh** A.R. Jalilian Geramifar Yousefnia Mazidi Beiki	Iran	Preclinical Evaluation of 68Ga-MAA from Commercial Available 99mTc-MAA kit
373	**K. Mai-Trong** T. Nguyen-Thi H. Tran-Dinh T. Ngo-Thuy	Vietnam	Study on the Preparation and Quality Control of Labelled Monoclonal Antibody 131i-Rituximab for Non-Hodgkin Lymphoma Therapy
393	A.M. Senisik A.Y. Kilcar E. Ucar K. Ari Y. Parlak B.E.S. Bilgin **S. Teksoz**	Turkey	Biological Evaluation of a [18F]FDG-Labeled Small Peptide as an Imaging Agent
399	**I. Al Jammaz** B. Al-Otaibi S. Okarvi	Saudi Arabia	Optimized Preparation and Preclinical Cardiac Characteristic Evaluation of Novel [^{18}F]-FDG-Rhodamine as Potential PET Myocardial Perfusion Imaging Agent
400	D. Mwanza Wanjeh A. Alemu J.M. Muchira **E. Janevik**	Republic of Macedonia	Establishment and Development of Good Radiopharmacy Practice in Eastern Africa - Tool for Recognized Young Radiopharmacists and Prospective for Nuclear Medicine
Radiation Protection for Personnel and Patients			
56	O. Prakash	India	Strategically Designed F-18 FDG(PET) Hot Lab Can Drastically Reduce Whole Body Radiation Exposure to Medical Personnel
73	**M. Marengo** A. Infantino G. Cicoria D. Mostacci	Italy	Optimization of Site planning of PET Cyclotrons Using Monte Carlo simulations

No of Poster IAEA-CN-232-	Name	Designating Member State/Organization	Title of Paper
95	**C.F. Calderón Marín** J.J. González-González C. Duménigo-Ámbar W. Quesada-Cepero B. Sinconegui-Gómez Y. Solá-Rodríguez M. Guerrero-Cancio	Cuba	Radiation Safety Analysis During the Design of PET/CT Facilities
112	**J. Rodríguez**	Chile	Shielding Calculations of PET/CT Facility and Effective Dose to Staff Members
143	**E. Avila-Ramirez** L.S. Veloza-Salcedo G. Villalobos-Benitez	Mexico	Low Activity of 99mtc-Tetrofosmin for Reducing Effective Radiation Dose in Patients Undergoing Myocardial Scintigraphy
145	**J.L. Sablay** N. de Vera	Philippines	Organ and Effective Dose Estimates of Filipino Adult Patients from Whole-Body 18F-Fluorodeoxyglucose PET/CT Examinations
165	**T. Donmoon** W. Chamroonrat W. Changmuang S. Amnuaywattakorn C. Sritara M. Tuntawiroon	Thailand	Occupational Radiation Doses to Personnel from F-18 FDG PET/CT Procedures for Tumor Imaging in Ramathibodi Hospital
183	**H. Speckter**	Dominican Republic	Design of inexpensive, Robust and Non-interactive Waste Water Retention Tanks for Diagnostic and Therapeutic Nuclear Medicine Facilities
215	**H. Ndagire**	Uganda	Patient Safety when Using PET-CT Compared to other Modality of Imaging.
233	**N. Sirag** A. Hussein	Egypt	Radiation Protection in Design of PET-CT Facility to Reduce Doses for Occupational Personnel and Patients
268	**W. Zhai** W. He	China	The Utility of Automatic Dispenser in Nuclear Medicine
300	**J. Hudzietzová** M. Fulop P. Ragan J. Sabol	Czech Republic	Improvements in the Identification of the Maximum Skin Exposure and the Position of its Maximum on the Surface of Hands of Workers Handling Selected Radiopharmaceuticals
312	**E. Mora-Ramírez** M. Salas-Ramírez I. Berrocal-Gamboa C. Fonseca-Zamora	Costa Rica	Radiation Protection Recommendations for Releasing Patients Treated With 131i for Thyroid Cancer: Theoretical Considerations for Specific Patient Approach
341	**A. Mayer González**	Mexico	Comparative Analysis of the Shilding Requeriments for PET, Between AAPM 108 and The Maximum Activity Requested.

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
355	**I.K. Budak** H. Ozpinar N. B. Akyildiz M. Urhan	Turkey	Use of Digital Electronic Personnel Dosemeter to Improve the Staff from Radiation Protection
370	**F. Zito** G. Galetta L. Rossi L. Florimonte C. Canzi F. Voltini R. Benti E. Orunesu	Italy	18F-FDG Whole Body PET/CT: Dose Evaluation in Pediatric Patients
Quality Management in Nuclear Medicine and Diagnostic Imaging			
30	**A.C. Jiménez** J. Villalobos-Rosales G. Castro A. Alfaro	Costa Rica	An Overview of the Impact Caused by the Quality Management Audit in Nuclear Medicine Practices (QUANUM) at the Hospital Rafael Ángel Calderón Guardia
38	**P. Pusuwan**	Thailand	Quality Management in Nuclear Medicine: Experience in Siriraj Hospital, Thailand
71	**N. Raina** A. Sen A. Pathak D.R. Jangid	India	Daily System Quality Check –Essential for PET/CT Performance
138	**E. Lemos-Pereira** M. Fernandes A. Garcia L. Oliveira P. Colarinha	Portugal	An Example of a Standardization Methodology Applied to Bone Imaging, within the Auspices of the Quality Management System
194	**C. Arroyo-Castelán**	Mexico	Importance of the Technical Procedures Manual in Areas of Nuclear Medicine (PET/CT)
212	**S. Somanesan**	Singapore	The Impact of a QUANUM Audit on the Practice of Nuclear Medicine.
367	**M. Y Herrassi** **F. Bentayeb**	Morocco	Survey of Quality Control Equipment in Moroccan Nuclear Medicine Centres
Ethics, Leadership and Education for Nuclear Medicine and Diagnostic Imaging Professionals			
45	**R. Morales**	Peru	Multidisciplinary Teams Enhance Diagnosis and Treatment in Nuclear Medicine
119	**M.M. Hasan** F. Nasreen	Bangladesh	Asian School of Nuclear Medicine – An Emerging Platform of Nuclear Medicine Education

No of Poster IAEA-CN-232-	*Name*	*Designating Member State/Organization*	*Title of Paper*
127	**S. Saeed**	Pakistan	Nuclear Medicine Education in Pakistan—Past, Present and Future
181	**A. Rey** M. Terán A. León E. Savio	Uruguay	Implementation of a Flexible Radiopharmacy Postgraduate Programme in Uruguay for the Region: Acting Locally, Thinking Globaly.
269	S. Chen **H. Shi**	China	To Investigate the Nuclear Medicine PET/CT Standardized Training Model
397	**A. Urgrinska** D. Miladinova	Republic of Macedonia	Continuous Medical Education of Nuclear Medicine Professionals in Macedonia

PARTICIPATION IN IAEA SCIENTIFIC MEETINGS

Governments of Member States and those organizations whose activities are relevant to the meeting subject matter are invited to designate participants in IAEA scientific conferences and symposia. In addition, the IAEA itself may invite a limited number of scientists as invited speakers. Only participants designated or invited in this way are entitled to present papers and take part in the discussions.

Representatives of the press, radio, television or other information media and members of the public, the latter as 'observers', may also be authorized to attend, but without the right to take part in the proceedings.

Scientists interested in participating in any of the IAEA meetings should request information from the Government authorities of their own countries, in most cases the Ministry of Foreign Affairs or national atomic energy authority.

IAEA PUBLICATIONS RELATED TO THE SUBJECT OF THE CONFERENCE

STI/PUB/1393	IAEA Human Health Series No. 1: Quality Assurance for PET and PET/CT Systems	2009
STI/PUB/1381	IAEA Human Health Series No. 2: Quality Assurance Programme for Screen-film Mammography	2009
STI/PUB/1425	IAEA Human Health Series No. 4: Comprehensive Clinical Audits of Diagnostic Radiology Practices: A Tool for Quality Improvement. Quality Assurance Audit for Diagnostic Radiology Improvement and Learning (QUAADRIL)	2010
STI/PUB/1437	IAEA Human Health Series No. 5: Radiolabelled Autologous Cells: Methods and Standardization for Clinical Use	2015
STI/PUB/1394	IAEA Human Health Series No. 6: Quality Assurance for SPECT Systems	2009
STI/PUB/1416	IAEA Human Health Series No. 8: Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides	2009
STI/PUB/1438	IAEA Human Health Series No. 9: Appropriate Use of FDG-PET for the Management of Cancer Patients	2010
STI/PUB/1457	IAEA Human Health Series No. 11: Planning a Clinical PET Centre	2010
STI/PUB/1491	IAEA Human Health Series No. 16: Atlas of Bone Scintigraphy in the Developing Paediatric Skeleton: The Normal Skeleton Variants and Pitfalls	2011
STI/PUB/1482	IAEA Human Health Series No. 17: Quality Assurance Programme for Digital Mammography	2011
STI/PUB/1516	IAEA Human Health Series No. 18: Nuclear Cardiology: Its Role in Cost Effective Care	2012
STI/PUB/1557	IAEA Human Health Series No. 19: Quality Assurance Programme for Computed Tomography: Diagnostic and Therapy Applications	2012

STI/PUB/1560	IAEA Human Health Series No. 20: Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) for Neuroendocrine Tumours	2013
STI/PUB/1566	IAEA Human Health Series No. 23: Nuclear Cardiology: Guidance and Recommendations for Implementation in Developing Countries	2012
STI/PUB/1609	IAEA Human Health Series No. 24: Dosimetry in Diagnostic Radiology for Paediatric Patients	2013
STI/PUB/1610	IAEA Human Health Series No. 25: Roles and Responsibilities, and Education and Training Requirements for Clinically Qualified Medical Physicists	2013
STI/PUB/1616	IAEA Human Health Series No. 26: Standard Operating Procedures for PET/CT: A Practical Approach for Use in Adult Oncology	2013
STI/PUB/1642	IAEA Human Health Series No. 27: PET/CT Atlas on Quality Control and Image Artefacts	2014
STI/PUB/1648	IAEA Human Health Series No. 29: Guided Intraoperative Scintigraphic Tumour Targeting (GOSTT) Implementing Advanced Hybrid Molecular Imaging and Non-imaging Probes for Advanced Cancer Management	2014
STI/PUB/1680	IAEA Human Health Series No. 32: Clinical PET/CT Atlas: A Casebook of Imaging in Oncology	2015
STI/PUB/1498	IAEA Human Health Reports No. 4: Implementation of the International Code of Practice on Dosimetry in Diagnostic Radiology (TRS 457): Review of Test Results	2011
STI/PUB/1605	IAEA Human Health Reports No. 9: Quantitative Nuclear Medicine Imaging: Concepts, Requirements and Methods	2014
IAEA-TECDOC-1714	IAEA TECDOC No. 1714: Management of Discharge of Low Level Liquid Radioactive Waste Generated in Medical, Educational, Research and Industrial Facilities	2013

IAEA-TECDOC-1605	IAEA TECDOC No. 1605: A Guide to Clinical PET in Oncology: Improving Clinical Management of Cancer Patients	2008
IAEA-TECDOC-1597	IAEA TECDOC No. 1597: Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System	2008
IAEA-TECDOC-1549	IAEA TECDOC No. 1549: Criteria for Palliation of Bone Metastases — Clinical Applications	2007
IAEA-TECDOC-1414	IAEA TECDOC No. 1414: Development of Kits for 99mTc Radiopharmaceuticals for Infection Imaging. Report of a co-ordinated research project 2000–2003	2004
IAEA-TECDOC-1608	IAEA TECDOC No. 1608: Nuclear Medicine in Thyroid Cancer Management: A Practical Approach	2008
IAEA-TECDOC-1537	IAEA TECDOC No. 1537: Strategy and Methodology for Radioactive Waste Characterization	2007
IAEA-TECDOC-1603	IAEA TECDOC No. 1603: The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment	2008
IAEA-TECDOC-1430	IAEA TECDOC No. 1430: Radioisotope Handling Facilities and Automation of Radioisotope Production	2004
IAEA-TECDOC-1498	IAEA TECDOC No. 1498: Development of Radioimmunometric Assays and Kits for Non-clinical Applications – Proceedings of a final research coordination meeting held in Vienna, 6–10 December 2004	2006
IAEA-TECDOC-1183	IAEA TECDOC No. 1183: Management of radioactive waste from the use of radionuclides in medicine	2000
STI/PUB/1141	Non-serial Publications: IAEA Quality Control Atlas for Scintillation Camera Systems	2003
STI/PUB/1198	Non-serial Publications: Nuclear Medicine Resources Manual	2006
STI/PUB/1342	Non-serial Publications: Operational Guidance on Hospital Radiopharmacy. A Safe and Effective Approach	2008

STI/PUB/1371	Non-serial Publications: Quality Management Audits in Nuclear Medicine Practices	2009
STI/PUB/1344	Non-serial Publications: Strategies for Clinical Implementation and Quality Management of PET Tracers	2009
STI/PUB/1617	Non-serial Publications: Nuclear Medicine Physics: A Handbook for Teachers and Students	2015
IAEA-TCS-50	Training Course Series No. 50: Clinical Training of Medical Physicists specializing in Nuclear Medicine	2011
IAEA-TCS-39	Training Course Series No. 39: Competency Based Hospital Radiopharmacy Training	2010
STI/PUB/1405	IAEA Radioisotopes and Radiopharmaceuticals Series No.1: Technetium-99m Radiopharmaceuticals: Status and Trends	2010
STI/PUB/1436	IAEA Radioisotopes and Radiopharmaceuticals Series No.2: Production of Long Lived Parent Radionuclides for Generators: ^{68}Ge, ^{82}Sr, ^{90}Sr and ^{188}W	2010
STI/PUB/1515	IAEA Radioisotopes and Radiopharmaceuticals Series No.3: Cyclotron Produced Radionuclides: Guidance on Facility Design and Production of [^{18}F] Fluorodeoxyglucose (FDG)	2012
STI/PUB/1662	IAEA Radioisotopes and Radiopharmaceuticals Series No.5: Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy	2015
STI/PUB/1674	IAEA Radioisotopes and Radiopharmaceuticals Series No.6: Radiopharmaceuticals for Sentinel Lymph Node Detection: Status and Trends	2015
STI/PUB/1348	IAEA Nuclear Security Series No. 9: Security in the Transport of Radioactive Material	2008
STI/PUB/1387	IAEA Nuclear Security Series No. 11: Security of Radioactive Sources	2009

STI/PUB/1088	IAEA Safety Standards Series No. WS-G-2.3: Regulatory Control of Radioactive Discharges to the Environment Safety Guide	2000
STI/PUB/1093	IAEA Safety Standards Series No. GS-R-1: Legal and Governmental Infrastructure for Nuclear, Radiation, Radioactive Waste and Transport Safety	2000
STI/PUB/1117	IAEA Safety Standards Series No. RS-G-1.5: Radiological Protection for Medical Exposure to Ionizing Radiation. Safety Guide	2002
STI/PUB/1192	IAEA Safety Standards Series No. GS-G-1.5: Regulatory Control of Radiation Sources. Safety Guide	2004
STI/PUB/1227	IAEA Safety Standards Series No. RS-G-1.9: Categorization of Radioactive Sources Safety Guide	2005
STI/PUB/1269	IAEA Safety Standards Series No. TS-G-1.3: Radiation Protection Programmes for the Transport of Radioactive material	2007
STI/PUB/1253	IAEA Safety Standards Series No. GS-G-3.1: Application of the Management System for Facilities and Activities	2006
STI/PUB/1467	IAEA Safety Standards Series No. GSG-2: Criteria for Use in Preparedness and Response for a Nuclear or radiological Emergency	2011
STI/PUB/1465	IAEA Safety Standards Series No. GSR Part 1: Governmental, Legal and Regulatory Framework for Safety. General Safety Requirements Part 1	2010
STI/PUB/1570	IAEA Safety Standards Series No. SSR-6: Regulations for the Safe Transport of Radioactive Material	2012
STI/PUB/1578	IAEA Safety Standards Series No. Radiation Protection and Safety of Radiation Sources: International Basic Safety standards:	2014

STI/PUB/1543	Safety Reports Series No. 71: Radiation Protection in Paediatric Radiology	2012
STI/PUB/1417	Safety Reports Series No. 63: Release of Patients After Radionuclide Therapy	2009
STI/PUB/1207	Safety Reports Series No. 40: Applying Radiation Safety Standards in Nuclear Medicine	2005
STI/PUB/1118	Safety Reports Series No. 21: Optimization of Radiation Protection in the Control of Occupational Exposure	2002
STI/PUB/1366	Safety Reports Series No. 60: Radiation Protection in Newer Medical Imaging Techniques: Cardiac CT	2009
STI/PUB/1343	Safety Reports Series No. 58: Radiation Protection in Newer Medical Imaging Techniques: PET/CT	2008
STI/PUB/1294	Technical Reports Series No. 457: Dosimetry in Diagnostic Radiology: An International Code of Practice	2007
STI/DOC/010/454	Technical Reports Series No. 454: Quality Assurance for Radioactivity Measurement in Nuclear Medicine	2006
STI/DOC/010/458	Technical Reports Series No. 458: Comparative Evaluation of Therapeutic Radiopharmaceuticals	2007
STI/DOC/010/470	Technical Reports Series No. 470: Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators	2009
STI/DOC/010/471	Technical Reports Series No. 471: Cyclotron Produced Radionuclides: Guidelines for Setting Up a Facility	2009
STI/DOC/010/468	Technical Reports Series No. 468: Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods	2009
STI/DOC/010/465	Technical Reports Series No. 465: Cyclotron Produced Radionuclides: Principles and Practice	2008
STI/DOC/010/459	Technical Reports Series No. 459: Labelling of Small Biomolecules Using Novel Technetium-99m Cores	2007
STI/DOC/010/466	Technical Reports Series No. 466: Technetium-99m Radiopharmaceuticals: Manufacture of Kits	2008
STI/DOC/010/473	Technical Reports Series No. 473: Nuclear Data for the Production of Therapeutic Radionuclides	2011

FORTHCOMING SCIENTIFIC MEETINGS SCHEDULED BY THE IAEA

2015

Organizational Meeting of the Convention on Nuclear Safety 15 October, Vienna, Austria

International Conference on Global Emergency Preparedness and Response 19–23 October, Vienna, Austria

2016

International Conference on Human and Organizational Aspects of Assuring Nuclear Safety – Exploring 30 Years of Safety Culture 22-15 February; Vienna, Austria

International Conference on Effective Nuclear Regulatory Systems: Sustaining Improvements Globally 11-15 April; Vienna, Austria

International Conference on Advancing the Global Implementation of Decommissioning and Environmental Remediation Programmes 23-27 May; Madrid, Spain

International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC 2016) 10-14 October; Vienna, Austria

3rd International Conference on Nuclear Knowledge Management – Challenges and Approaches 7-11 November; Vienna, Austria

International Conference on the Safety of Radioactive Waste Management 21-25 November; Vienna, Austria

2nd International Conference on Nuclear Security 5-9 December; Vienna, Austria

For information on forthcoming scientific meetings, please consult the IAEA web site: http://www.iaea.org/

NOTES

NOTES

NOTES